 Effects of Code Sepsis Implementation on ED Sepsis Care (Code Sepsis)    Protocol version: Version 9.0  Updated:  February 1, 2023  Principal Investigator:  Ithan Peltan, MD, MSc      Trial steering committee: Ithan Peltan, MD, MSc    Samuel Brown, MD, MPH    Joseph Bledsoe, MD  Facilities involved: Intermountain Medical Center  Utah Valley Hospital   Dixie Regional Medical Center  Sponsor:  National Institutes of Health (1K23 GM12966-01A1)     
Code Sepsis I protocol Version 3.0 
 1 TABLE OF CONTENTS  1.	ABBREVIATIONS	AND	DEFINITIONS	..........................................................................................	4	1.1 Abbreviations	...............................................................................................................................................	4	1.2 Definitions	.....................................................................................................................................................	5	2. STUDY SUMMARY	................................................................................................................................	6	2.1 Title	................................................................................................................................................................	6	2.2 Primary Objective	........................................................................................................................................	6	2.3 Primary Hypothesis	.....................................................................................................................................	6	2.4 Study Design	.................................................................................................................................................	6	2.4.1 Study groups and phases	..................................................................................................................................................	6	2.4.2 Inclusion criteria	...................................................................................................................................................................	6	2.4.3 Exclusion criteria	..................................................................................................................................................................	6	2.4.5 Primary analysis cohort	.....................................................................................................................................................	7	2.4.6 Primary outcome	.................................................................................................................................................................	7	2.4.7 Secondary outcomes	..........................................................................................................................................................	7	2.4.8 Data analysis	..........................................................................................................................................................................	7	2.4.9 Sample size	.............................................................................................................................................................................	7	3. TRIAL DESCRIPTION	.............................................................................................................................	8	3.1 Background	...................................................................................................................................................	8	3.2 Overall Study Motivation, Aim and Hypothesis	.....................................................................................	8	3.3 Primary Objective	........................................................................................................................................	9	3.4 Primary Hypothesis	.....................................................................................................................................	9	3.5 Study Overview	............................................................................................................................................	9	3.6 Analysis cohorts	.........................................................................................................................................	10	3.6.1 Primary analysis cohort	..................................................................................................................................................	10	3.6.2 Secondary and sensitivity analysis cohorts	..............................................................................................................	10	3.6.3 Subgroups	............................................................................................................................................................................	10	3.7 Endpoints	....................................................................................................................................................	10	3.7.1 Primary outcome	..............................................................................................................................................................	10	3.7.2 Secondary outcomes	.......................................................................................................................................................	10	4. STUDY POPULATION AND ENROLLMENT	.....................................................................................	12	4.1 Setting	..........................................................................................................................................................	12	4.2 Study Population	........................................................................................................................................	12	4.2.1 Exposure groups	................................................................................................................................................................	12	4.2.2 Inclusion criteria:	...............................................................................................................................................................	13	4.2.3 Exclusion criteria:	..............................................................................................................................................................	13	4.2.4 Inclusion/exclusion criteria rationale	.........................................................................................................................	13	4.3 Waivers of Informed Consent and HIPAA authorization	.....................................................................	13	4.4 Minorities and Women	.............................................................................................................................	13	4.5 Vulnerable Subjects	...................................................................................................................................	13	5. STUDY PROCEDURES	........................................................................................................................	15	5.1 Standard Care	.............................................................................................................................................	16	5.2 Code Sepsis Protocol	.................................................................................................................................	16	6. DATA COLLECTION AND VARIABLES	..............................................................................................	18	6.1 Data Collection	...........................................................................................................................................	18	6.2 Anonymous Data Collection For Protocol Development and During Live Code Sepsis Activation	.............................................................................................................................................................................	18	6.3 Active Follow-Up for Patients Undergoing Code Sepsis	......................................................................	18	
Code Sepsis I protocol Version 3.0 
 2 6.4 Protected Health Information	.................................................................................................................	18	6.5 Variables/data elements	..........................................................................................................................	18	6.6 Data Management	.....................................................................................................................................	20	7. DATA ANALYSIS	.................................................................................................................................	21	7.1 Introduction to Quasi-Experimental Analysis	.......................................................................................	21	7.2 Multivariable models	................................................................................................................................	21	7.3 Sample size/power analysis	.....................................................................................................................	21	8. RISK ASSESSMENT	............................................................................................................................	23	8.1 Potential Risks	............................................................................................................................................	23	8.1.1 Risk of confidentiality breach	.......................................................................................................................................	23	8.1.2 Risks for control group patients	...................................................................................................................................	23	8.1.3. Risks to patients exposed to the Code Sepsis protocol	......................................................................................	23	8.2 Alternatives to Participation	....................................................................................................................	23	8.3 Minimization of Risks	................................................................................................................................	23	8.3.1 Protections against invasion of privacy or breach of confidentiality	..............................................................	24	8.3.2 Incidental findings	............................................................................................................................................................	24	8.3.3 Protection against medicolegal risk	............................................................................................................................	24	8.3.4 Optimization of Code Sepsis targeting	......................................................................................................................	24	8.3.4 Protections against overtreatment and anchoring bias	......................................................................................	24	8.3.5 Protections against overtreatment and adverse drug reactions	......................................................................	25	8.4 Potential Benefits of the Proposed Research to Human Subjects and Others	................................	25	8.5 Importance of the Knowledge to be Gained	.........................................................................................	25	9. HUMAN SUBJECTS	............................................................................................................................	26	9.1 Selection of Subjects	.................................................................................................................................	26	9.2 Waiver of Informed Consent and HIPAA Authorization	......................................................................	26	9.2.1 Research involves no more than minimal risk	........................................................................................................	26	9.2.2 No adverse effects on the rights and welfare of participants	...........................................................................	26	9.2.3 The research could not practicably be carried out without waiver of informed consent	.......................	26	9.2.4 Information on the Code Sepsis protocol and study will be available to all ED patients	.........................	27	9.2.5 The minimal necessary amount of protected information will be obtained	...............................................	27	9.2.6 All data, including PHI, will be securely guarded from improper disclosure	................................................	27	10. MONITORING AND SAFETY REPORTING	.....................................................................................	28	10.1 Potential Risks and Benefits for Participants	......................................................................................	28	10.2 Adverse Event and Serious Adverse Event Collection	.......................................................................	28	10.2.1 Adverse event	..................................................................................................................................................................	28	10.2.2 Serious Adverse Event (SAE)	.......................................................................................................................................	29	10.2.3 Adverse event monitoring	...........................................................................................................................................	29	10.3 Adverse Event and Serious Adverse Event Reporting	.......................................................................	29	10.4 Interim Analysis	.......................................................................................................................................	30	10.5 Data and Safety Monitoring	...................................................................................................................	30	10.5.1 Safety Monitoring Procedures	...................................................................................................................................	30	10.5.2 Enrollment, procedure, regulatory, and data quality monitoring	.................................................................	31	10.5.3 Frequency of data and safety monitoring	..............................................................................................................	31	10.5.4 Independent safety monitor identify and affiliation	..........................................................................................	31	10.5.5 Conflict of interest for independent safety monitor	..........................................................................................	31	10.5.6 Independent safety monitor responsibilities	........................................................................................................	31	10.6 Confidentiality During Adverse Event Reporting	...............................................................................	32	11. BIBLIOGRAPHY	................................................................................................................................	33	APPENDIX	A	—	Eligible	IV	and	IV-equivalent	antibiotics	....................................................	35	
Code Sepsis I protocol Version 3.0 
 3 APPENDIX	B	—	“Sepsis	mimic”	ICD	codes	.................................................................................	37	B.1	Heart	failure	diagnosis	codes1	..........................................................................................................	37	B.2	Pulmonary	embolism	diagnosis	codes1,2	.......................................................................................	38	B.3	Deep	vein	thrombosis	diagnosis	codes1,2	......................................................................................	39	APPENDIX	C	—	Diagnosis	codes	for	adverse	drug	reaction	................................................	42				
Code Sepsis I protocol Version 3.0 
 4 1. ABBREVIATIONS AND DEFINITIONS  1.1 Abbreviations  AE = Adverse event CHF = Congestive heart failure ED = Emergency Department GCS = Glasgow Coma Scale  HIPAA = Health Insurance Portability and Accountability Act IRB = Institutional Review Board ICU = Intensive Care Unit   ICD-9-CM = International Classification of Disease, version 9, clinical modification ICD-10-CM = International Classification of Disease, version 10, clinical modification INR = International normalized ratio  ISM = Independent safety monitor ITT = Intent to treat  MAP = Mean arterial pressure NIH = National Institutes of Health PE = Pulmonary embolism PI = Principle investigator PHI = Protected Health Information REDCap = Research Electronic Data Capture RR = Respiratory rate SOFA score = Sequential Organ Failure Assessment score  SBP = Systolic blood pressure  SpO2 = Oxygen saturation via pulse oximetry  SUSAR = Serious and Unexpected Suspected Adverse Reactions  SAEs= Serious Adverse Events  WBC = White blood cell count     
Code Sepsis I protocol Version 3.0 
 5 1.2 Definitions  • Adverse Event: Any untoward medical occurrence associated with the use of a drug or a study procedure, whether or not considered drug related.  • Adverse reaction: An adverse reaction means any adverse event caused by a study intervention. An adverse reaction is a subset of all suspected adverse reactions where there is a reason to conclude that the study intervention caused the event.  • Door-to-antibiotic time: Primary outcome; the time from the first recorded arrival time in ED (usually ED triage or registration) and the time the first eligible antibiotic was administered.  • Hypotension: SBP <90 mmHg or MAP <65 mmHg or, where applicable, receipt of vasopressor medication • Intention to Treat (ITT): All eligible patients who present to the ED will be included in the ITT cohort for the purposes of analyzing the primary and secondary study outcomes.  • PHI: identifiable health information that is used, maintained, stored, or transmitted by a HIPAA-covered entity • SAEs: Serious Adverse Events Adverse events that are serious and unexpected and have a reasonable possibility that the event was due to a study procedure  • Sepsis: Life-threatening organ dysfunction resulting from a dysregulated host response to infection, clinically identified in the emergency department (ED) by an acute rise in the Sequential Organ Failure Assessment (SOFA) score while in the ED ≥2 points above baseline plus suspected or confirmed infection in the ED.1 • Sepsis mimic: Clinical condition which may cause patient to exhibit and/or be treated for sepsis even though infection is not actually present. For the present study, pulmonary embolism (PE) and congestive heart failure (CHF) have been identified as sepsis mimic conditions. • Septic shock: Sepsis associated with hypotension requiring administration of vasopressors. • Study hospital: Defined as the hospital where the patient presented to the ED. • Suspected adverse reaction: any adverse event for which there is a reasonable possibility that the study procedures caused the adverse event. Reasonable possibility means there is evidence to suggest a causal relationship between the study procedures and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction (21 CFR 312.32(a)).  • Suspected or confirmed infection in the emergency department: Identified based on clinical behaviors of clinicians as the combination of administration of an IV- or IV-equivalent antibiotic plus collection of a body fluid culture or a positive molecular test for infection. • Suspected Unexpected Serious Adverse Reaction (SUSAR) An adverse reaction that is both unexpected (not consistent with the risks outlined in the protocol or investigator brochure), serious, and meets the definition of a Suspected Adverse Reaction      
Code Sepsis I protocol Version 3.0 
 6 2. STUDY SUMMARY  2.1 Title Effects of Code Sepsis Implementation on ED Sepsis Care (Code Sepsis)  2.2 Primary Objective Determine the effects of reorganizing ED sepsis care (Code Sepsis protocol) on door-to-antibiotic time for ED patients with sepsis.  2.3 Primary Hypothesis Early activation of a multidisciplinary, coordinated, team-based assessment and treatment protocol for patients with potential sepsis will decrease door-to-antibiotic time for ED patients with sepsis.  2.4 Study Design Pragmatic phase 2a pre/post single-center implementation study with contemporaneous controls testing reorganization of standard ED sepsis care around a protocol for early, coordinated, multidisciplinary protocol for assessment of patients with potential sepsis (Code Sepsis protocol). 1. We will emphasize pragmatic, real-world implementation of the Code Sepsis protocol in a single ED. 2. We will compare care delivered to ED patients after Code Sepsis protocol implementation in the intervention ED to care received in this ED prior to Code Sepsis implementation. 3. We will conduct a quasi-experimental analysis using contemporaneous control data obtained from two non-intervention hospitals to control for temporal trends in studied outcomes not resulting from the tested intervention. 4. We will measure the effects of protocol implementation on all ED patients with sepsis (including patients not treated under the Code Sepsis protocol) as well as potential bystander effects.  2.4.1 Study groups and phases Phase #1: Pre intervention (November 13, 2018 to November 12, 2019) • Control EDs: Standard care • Intervention ED: Standard care Phase #2: Intervention roll-in (November 13, 2019 to February 12, 2020) • Control EDs: Standard care • Intervention ED: Launch and fine-tuning of Code Sepsis protocol, fine tuning of Code Sepsis activation mechanism.  Phase #3: Full intervention (February 13, 2020 to February 12, 2021) • Control EDs: Standard care • Intervention ED: Full implementation of Code Sepsis protocol  2.4.2 Inclusion criteria 1. Age ≥18 years 2. Arrival to intervention or a control ED during study period  2.4.3 Exclusion criteria 1. Age <18 years 
Code Sepsis I protocol Version 3.0 
 7 2. Trauma patient  2.4.5 Primary analysis cohort ED patients with clinical sepsis, as identified by the combination of 1) Acute organ failure: SOFA score while in the ED ≥2 points above baseline 2) Suspected or confirmed infection while in the ED, as identified by both: a) Administration of ≥1 IV or IV-equivalent antibiotics while in the ED b) Collection of ≥1 body fluid cultures while in the ED  2.4.6 Primary outcome Door-to-antibiotic time  2.4.7 Secondary outcomes • Mortality (including 30-day, 1-year, hospital) • Hospital charges • Hospital length of stay • Code Sepsis activation rate  • Code Sepsis activation accuracy • Antibiotic utilization fraction • Antibiotic spectrum • Antibiotic overtreatment rate • Adverse drug & allergic reaction incidence (e.g. anaphylaxis, new onset Clostridium difficile infection)  2.4.8 Data analysis The primary analysis will use quasi-experimental methods to compare sepsis patients’ adjusted mean door-to-antibiotic time (primary outcome) at the intervention hospital pre- versus post-implementation of the Code Sepsis protocol using the measured change at non-intervention hospitals to control for pre-versus post-intervention changes not attributable to protocol implementation. Secondary analyses will compare the change in secondary outcomes using similar methods.   2.4.9 Sample size Assuming 4.5 sepsis patients per day at the intervention ED, treatment of 30% of these patients by Code Sepsis teams during study phase #3, and 6 total sepsis patients daily in control EDs (all conservative estimates), I will have 90% power to detect a change ≥16 minutes in the overall average door-to-antibiotic time among all ED sepsis patients after Code Sepsis implementation at the intervention hospital.    
Code Sepsis I protocol Version 3.0 
 8 3. TRIAL DESCRIPTION  3.1 Background  Sepsis, the combination of infection and acute organ dysfunction, is a common, morbid, and often lethal syndrome.1,2 Sepsis hospitalizes 1.3 million patients each year, kills 20%, and costs $23.7 billion.2-4 Early, appropriate antibiotic initiation is critical: sepsis survival decreases with every hour’s delay. 5-13 While guidelines and government mandates thus emphasize prompt antibiotics, international guidelines’ have admitted a lack of data to support the feasibility or implementation of their one-hour door-to-antibiotic goal.14,15  Among patients presenting to the emergency department (ED) with sepsis, we previously found that non-patient contextual cues could improve rapid antibiotic initiation, whereas ED busyness was associated with delayed antibiotics.16,17 I also discovered five-fold variation between physicians in median door-to-antibiotic time.5 ED care reorganization could bypass these cognitive, stylistic, and resource barriers to timely sepsis treatment. In fact, ED protocols linking prehospital notification to a multidisciplinary, team-based response are common and effective for trauma, stroke, and myocardial infarction,18-22 conditions that are less common and less mortal than sepsis but require similarly time-sensitive treatment.23 Given that sepsis has a less definitive presentation, however, analogous protocols for sepsis could waste resources or promote anchoring bias and overtreatment of patients without sepsis, issues observed with door-to-antibiotic standards for pneumonia.24-26   We hypothesize that reorganizing ED sepsis care around multidisciplinary “Code Sepsis” teams activated prior to or upon patients’ ED arrival will reduce door-to-antibiotic times — with tolerable overtreatment rates — by mobilizing personnel, systematizing illness severity and infection risk assessment,27 facilitating test completion, and eliminating any gap between treatment decision and antibiotic infusion. This study will therefore evaluate the effectiveness and tradeoffs of a Code Sepsis program for ED sepsis patients.  3.2 Overall Study Motivation, Aim and Hypothesis Many emergency department (ED) patients with sepsis do not receive antibiotics and other care within intervals recommended in international guidelines. Efforts to accelerate treatment, however, may lead to overtreatment and other adverse effects. The goal of this project is to determine the potential effectiveness and tradeoffs of a Code Sepsis program for ED sepsis patients.  Aim:   Establish the feasibility and effects of a team-based Code Sepsis protocol designed to accelerate antibiotic initiation for ED patients with suspected sepsis.     Using preexisting infrastructure, implement prehospital- or triage-activated Code Sepsis ED teams in a single ED and compare sepsis patients’ door-to-antibiotic times pre- and post-implementation, controlling for unrelated temporal trends with observational data from two non-intervention EDs.   Hypothesis: Prehospital or triage-based activation of an ED team prepared to rapidly diagnose and treat sepsis decreases door-to-antibiotic time without increasing overtreatment.  
Code Sepsis I protocol Version 3.0 
 9 3.3 Primary Objective Determine the effect of reorganizing ED sepsis care (Code Sepsis protocol) on door-to-antibiotic time for ED patients with sepsis.  3.4 Primary Hypothesis Early activation of a multidisciplinary, coordinated, team-based assessment and treatment protocol for patients with potential sepsis will decrease door-to-antibiotic times for ED patients with sepsis.  3.5 Study Overview To assess feasibility and test the preliminary efficacy of ED-based Code Sepsis teams activated on or before patients’ ED arrival, we will pursue a Phase 2a implementation trial involving Code Sepsis team activation in one ED (Intermountain Medical Center [IMC]) while collecting contemporaneous control data at two other urban EDs (Utah Valley Hospital and Dixie Regional Medical Center [control sites], Table 1). • Months 1-12: Collect baseline data (all sites), refine Code Sepsis protocol, and train ED staff at IMC. Portions of baseline data may be collected in a retrospective fashion. At the intervention site during this period, we may also undertake preparatory work to Code Sepsis protocol launch, including anonymous patient care observations to evaluate care processes; pilot testing of the draft Code Sepsis protocol or its components; and testing of the accuracy of Code Sepsis activation mechanisms.  • Months 13-15: Run-in period: implement Code Sepsis protocol at IMC, optimize protocol & its trigger. • Months 25-36: Continue Code Sepsis protocol at site A (intervention ED). Continue standard care processes for sepsis without change (control condition) at two non-intervention EDs Using contemporaneous controls and rigorous statistical methods, we will assess how implementation of the Code Sepsis protocol affects process and patient outcomes in the intervention ED (Figure 1). Continuation of the Code Sepsis protocol (with or without revision) by the intervention ED and/or adoption elsewhere within the Intermountain Healthcare system is expected to be contingent on the results of these analyses.     Figure 1. Code Sepsis implementation and data collection for Aim III. 

Code Sepsis I protocol Version 3.0 
 10 3.6 Analysis cohorts 3.6.1 Primary analysis cohort ED patients with clinical sepsis, as identified by the combination of 1) Acute organ failure: SOFA score while in the ED ≥2 points above baseline 2) Suspected or confirmed infection while in the ED, as identified by both: c) Administration of ≥1 IV or IV-equivalent antibiotics while in the ED (see Appendix A) d) Collection of ≥1 body fluid cultures while in the ED  3.6.2 Secondary and sensitivity analysis cohorts 1) All eligible ED patients 2) ED patients with a “sepsis mimic” diagnosis based on a primary ICD-10 discharge diagnosis codes for congestive heart failure or venous thromboembolism with no diagnostic code for infection (see Appendix B).  3) “Likely” sepsis patients based on simple triage assessment to include fever and at least 1 out of 3 of hypotension (SBP <90 mmHg), altered mental status (GCS ≤14), or respiratory failure (RR ≥22 or SpO2 ≤85%).  3.6.3 Subgroups A priori subgroups will include: sex; hypotension (SBP <90 mmHg or MAP <65 mmHg) present on ED arrival.  3.7 Endpoints Analysis will be conducted on an intention to treat basis.   3.7.1 Primary outcome Door-to-antibiotic time among all ED sepsis patients. Door-to-antibiotic time is the time from the first recorded arrival time in ED (usually ED triage or registration) and the time the first eligible antibiotic was administered (Appendix A).  3.7.2 Secondary outcomes • Clinical/patient-centered secondary outcomes (measured among all ED sepsis patients): 1) All-cause mortality to day 30  2) All-cause mortality to 1 year  3) In-hospital all-cause mortality  4) Hospital charges: Amount charged to patient for their medical care during index ED visit and associated hospitalization. 5) Hospital length of stay  • Process/feasibility secondary outcomes 1) Code Sepsis activation rate: Measured as the percentage of all ED patients for whom the Code Sepsis protocol was activated.  2) Code Sepsis activation accuracy metrics. Accurate Code Sepsis activation is defined as activation for patients who have sepsis while in the ED and no activation for patients who do not have sepsis in the ED.  • Adverse effects and unintended outcomes of protocol implementation 
Code Sepsis I protocol Version 3.0 
 11 1) Antibiotic utilization percentage: measured as the fraction of  (1) all ED patients; (2) Code Sepsis activation patients; or (3) “likely” sepsis patients who received IV or IV-equivalent antibiotics. 2) Antibiotic spectrum: Total Stenehjem antibiotic spectrum score28 for all antibiotics administered in first 24 hours, measured for (1) all ED patients or (2) sepsis patients 3) Antibiotic overtreatment rate: Percentage of “sepsis mimic” patients who received IV or IV-equivalent antibiotics in the ED. 4) New onset C. difficile colitis incidence: Percentage of (1) all ED patients and (2) ED sepsis patients with a positive stool test for Clostridium difficile colitis between 72 hours and 90 days after ED arrival. 5) Adverse drug & allergic reaction incidence: Measured as the fraction of 1) all ED patients and (2) ED sepsis patients with a discharge diagnosis code consistent with anaphylaxis or with an adverse reaction to antibiotics (see Appendix C).  • Potential exploratory outcomes 1) Measures of organ failure trajectory, to include change in the SOFA score between hospital day 1 and hospital day 3, and overall and organ-specific measures of organ failure-free days through day 28.  § Organ-failure free days (OFFD) are defined as the number of days from the time of the first SOFA score ≤1 above baseline to day 28 after ED arrival, assuming survival for at least two consecutive calendar days after the SOFA score ≤1 above baseline and continued SOFA score ≤1 point above baseline to day 28. If a patient has SOFA score rise again to ≥2 points above baseline and subsequently achieves SOFA score ≤1 point above baseline to day 28, VFDs will be counted from the end of the last period of SOFA score ≤1 to day 28. If a patient had SOFA score ≥2 points above baseline at day 27 or dies prior to day 28, OFFD will be zero § Support-free days (i.e. ventilator-free days) are calculated similar to OFFD 2) Mortality at other intervals 3) Testing and treatment utilization. Outcomes measured among (1) among all ED sepsis patients; (2) all ED patients; (3) “likely” sepsis patients 4) Code Sepsis care process timing: measured among patients who received Code Sepsis protocol activation as time from protocol activation until completion of key protocol steps, to include blood culture collection, chest X-ray collection, team huddle, antibiotic initiation 5) Timing of testing & care processes among all sepsis patients, to include ED clinician assessment, ED room placement, ED departure, blood culture collection, radiology testing, and order entry for antibiotics. Measured analogous to door-to-antibiotic time. 6) Code Sepsis protocol adherence: measured as performance of protocol steps in correct order both individually and as a fraction of all possible.   
Code Sepsis I protocol Version 3.0 
 12 4. STUDY POPULATION AND ENROLLMENT  4.1 Setting Intermountain Healthcare (hereafter “Intermountain”) is a nonprofit health system based in Salt Lake City, Utah with 23 hospitals in Utah and Idaho. Code Sepsis implementation will occur in a teaching ED (IMC, my “home” hospital) providing 89,000 visits annually (2.8% with clinical sepsis) for an  economically and ethnically diverse population of 1.1 million in Salt Lake County, Utah plus referrals from Wyoming, Nevada, and Idaho. To avoid spillover effects, concurrent control data will be electronically abstracted from two Intermountain EDs (Utah Valley Hospital and Dixie Regional Medical Center) staffed by other physician groups (Table 1).  4.2 Study Population We will study adult, non-trauma patients from the IMC ED and two control EDs during three phases (Figure 1): baseline (1 year, standard care at all sites); run-in (3 months, IMC ED launches/fine tunes the Code Sepsis protocol); and Code Sepsis implementation (1 year, Code Sepsis at IMC, standard care in control EDs). For this pre/post implementation trial, in which there will be no direct patient contact and in which we are comparing current standard care processes to a new, redesigned standard care processes in a non-randomized fashion, all ED patients who meet inclusion and do not meet exclusion criteria will be included in the analysis.  4.2.1 Exposure groups The group within which patient is analyzed is determined by the combination of (1) when the patient presents to the ED and (2) which hospital/ED to which the patient presents (Figures 1 and 2).  A. Pre-implementation control group at non-intervention hospitals: Admission to ED at non-intervention hospitals (Utah Valley Hospital and Dixie Regional Medical Center) prior to Code Sepsis implementation (estimated N=135,000) B. Pre-implementation control group at intervention hospital: Admission to ED at IMC prior to Code Sepsis implementation (estimated N=100,000) C. Post-implementation control group at non-intervention hospitals: Admission to ED at non-intervention hospitals (Utah Valley Hospital and Dixie Regional Medical Center) after implementation of Code Sepsis protocol at IMC (estimated N=170,000) D. Exposure group: Admission to ED at IMC during full Code Sepsis implementation (estimated N=125,000)  Table 1. Study hospital characteristics Site Description Hospital beds ED beds Annual ED visits IMC Tertiary/teaching 472 56 89,000 Utah Valley Regional referral 395 28 49,000 DRMC Regional referral 321 35 65,000 
 Figure 2. Subject allocation by study phase and hospital 

Code Sepsis I protocol Version 3.0 
 13 4.2.2 Inclusion criteria: o ED patient at Intermountain Medical Center, Utah Valley Hospital, Dixie Regional Medical Center o ED arrival beginning 1 year prior to date of Code Sepsis implementation at Intermountain Medical Center and continuing through 15 months after Code Sepsis implementation date.  o Age ≥18 years  4.2.3 Exclusion criteria: o Age <18 years o Trauma patient  4.2.4 Inclusion/exclusion criteria rationale Patients <18 years of age are excluded because the mechanisms, manifestations, and management of sepsis in children <18 years of age are often distinct from those applicable to adults, and in fact will vary depending on age group across childhood. Additionally, children are managed in most EDs by a distinct team of clinicians using distinct protocols.  As such, prehospital or triage-based sepsis prediction models applicable to adults are unlikely to work for children <18 years. Due to the above issues, implementation of a single sepsis care protocol for individuals age <18 years and age ≥18 years would impair the efficacy, feasibility, and generalizability of the proposed Code Sepsis protocol. Trauma patients are excluded because clinical identification of these patients is straightforward and triggers preexisting team-based care protocols with options for prehospital activation.   4.2.5 Study phase dates ED patients arriving to study EDs will be assigned to a study phase based on their ED arrival date. • Phase #1 (pre-intervention analysis phase): November 13, 2018 to November 12, 2019 • Phase #2 (intervention roll-in): November 13, 2019 to February 12, 2020 • Phase #3 (full intervention analysis phase): February 13, 2020 to February 12, 2021  4.3 Waivers of Informed Consent and HIPAA authorization This study comparing standard care to a new form of standard care will be carried out under a waiver of informed consent and HIPAA authorization (see section 9).  4.4 Minorities and Women  Women and minorities will be enrolled in proportion to their representation in the population base from which this study was developed, specifically patients presenting to Intermountain hospitals located in Utah’s Salt Lake, Washington, and Weber Counties.  In order to provide generalizable data for the ED patient diagnosis groups studied in each Aim, there will be no specific selection criteria that differ between sex/gender and racial/ethnic groups. Hospitals in this study serve counties with a combined population of over 1.5 million individuals, including over 26% who are Hispanic or non-white race. We expect the sex, ethnic and racial mix of the enrolled patients to reflect the population served.  4.5 Vulnerable Subjects We anticipate that potentially vulnerable subjects are eligible for the study. Potentially vulnerable patient subjects include pregnant women, prisoners, and/or individuals with decisional impairment. The purpose of this project is to identify a cohort that reflects the diversity of the U.S. sepsis population. Therefore, we believe these individuals should not be excluded from the study since the study is of no more than minimal risk. 
Code Sepsis I protocol Version 3.0 
 14 1. Data on vulnerable population membership will not be explicitly collected, and in fact attempting to identify and exclude members of potentially vulnerable populations could increase risk to both vulnerable patients and the overall subject cohort.  2. Altered mental status is also a common manifestation or complication of sepsis. Excluding patients with decisional impairment would therefore severely bias results of the planned analyses. 3. In implementation studies such as this, it is generally not possible to exclude vulnerable subjects. Aim III’s intervention involves testing a new option for standard care for ED sepsis management, so excluding vulnerable populations could actually subject these patients to harm because exclusion would prevent their receiving standard care. Assessment for vulnerability status, moreover, would largely preclude the planned intervention by preventing activation of prehospital or ED triage alerts.   
Code Sepsis I protocol Version 3.0 
 15 5. STUDY PROCEDURES  This study will measure the effect of a redesign of standard care for ED sepsis patients, specifically implementation of Code Sepsis protocol at Intermountain Medical Center. The study will include three phases with two groups during each phase. The primary analysis will only use data from phases #1 and #3 (see Figure 1 and 2). Phase #0: Protocol development (1 year, overlaps with phase #1) • Control EDs: N/A • Intervention ED: A small number of suspected sepsis patients (<10) may undergo anonymous observation to understand care processes involved in ED sepsis care. In addition, testing and iterative optimization of the accuracy of the Code Sepsis activation may employ direct observation of care for a convenience sample of patients during ED triage and comparison of activation criteria to clinician judgment, final sepsis diagnosis based on chart review, and electronic sepsis queries. Finally, pilot testing of the draft protocol may be conducted on a small convenience sample of patients (<20) identified by ED clinicians as having possible sepsis. We will collect anonymous data about completion of Code Sepsis processes during pilot testing. Phase #1: Pre intervention (1 year) • Control EDs: Standard care • Intervention ED: Standard care.  Phase #2: Intervention roll-in • Control EDs: Standard care • Intervention ED: Launch and fine-tuning of Code Sepsis protocol, fine tuning of Code Sepsis activation mechanism.  Phase #3: Full intervention • Control EDs: Standard care • Intervention ED: Full implementation of Code Sepsis protocol Phase #4 (operational): Continuation of the Code Sepsis protocol (with or without revision) by the intervention ED and/or adoption elsewhere within the Intermountain Healthcare system is expected to be contingent on observed effects of protocol implementation. It is possible that an inadequate benefit/risk ratio could lead to a decision not to continue the Code Sepsis protocol.    
Code Sepsis I protocol Version 3.0 
 16 5.1 Standard Care Patients arriving to the control EDs (all study phases) and the intervention ED during study Phase #1 will receive care as per then-current ED practices and protocols, guided by clinician judgment within a system-wide care process model for sepsis. As of early 2019, ED standard care for sepsis applicable at all study sites includes a standardized Care Process Model, expected completion of a standardized checklist, and standardized order sets.  5.2 Code Sepsis Protocol The Code Sepsis protocol (Figure 3) has six steps developed in collaboration with ED-based study team members and ED leaders (including physicians, nurses, pharmacists, and others) from the implementation ED and the Intermountain system. The current draft protocol was further iteratively revised based on input derived from the proposed multidisciplinary team during in situ high-fidelity simulation and during informal/ad hoc operationally-oriented pilot testing of steps 1-5 during live patient care.  The below protocol will be adapted further prior to and after implementation to ensure the protocol is feasible, efficient, and functions as intended based on stakeholder input and, as needed, additional protocol element testing during simulation and/or live patient care. Further revision will occur, during the protocol run-in phase and as needed based on observed findings and stakeholder input.  
 Figure 3. Current Code Sepsis protocol based on iterative revision using simulation testing, stakeholder input, & live pilot testing.  1) Identify likely sepsis patient from prehospital notification call data (nurse), at ED triage (nurse/physician), or on ED room placement (nurse or physician), adapting local and national practice for stroke team activation.29,30  2) Mobilize ED personnel and equipment to meet patients on arrival to the ED room using methods and communication networks already developed for ED trauma and stroke teams. 3) Concurrent patient evaluation and data collection by multiple disciplines (20-25 minutes), to include bedside assessment (e.g. history, examination, vital signs, allergy and medication history) by the physician, nurse and pharmacist; IV placement; blood and urine sampling; point-of-care laboratory testing, including lactate and urinalysis; and portable X-ray imaging. Appropriate therapeutic interventions will continue in parallel during the nominal data collection phase. 4) Team “huddles” to decide if sepsis diagnosis has been confirmed, disproven, or remains indeterminate. The physician may complete this step by announcing clinical decision-making to the team at any time. The nurse will request a decision huddle at 25 minutes into the Code Sepsis event if it has not previously been performed.  

Code Sepsis I protocol Version 3.0 
 17 5) Proceed with next therapeutic and/or diagnostic steps including, for confirmed sepsis patients, immediate initiation of an appropriate antibiotic regimen chosen from a range of options contained in a Code Sepsis antibiotic pack brought to the bedside by a pharmacist on protocol activation. Code Sepsis antibiotic regimens have been selected based on published guidelines and local antibiotic resistance patterns with input from ED clinicians, pharmacists, and infectious disease/antibiotic stewardship personnel. 6) If initial huddle pronounced sepsis status as “indeterminate,” return to step #4 after additional 20-25 minutes to follow up on additional diagnostic results (e.g. urinalysis, complete blood count 7) For antibiotic-treated patients, follow-up by antibiotic stewardship pharmacist active de-escalation or cessation as appropriate.  Additional protocol elements/details: • Code Sepsis team members:  o   ED attending physician +/- ED resident physician or medical student o   ED triage nurse o   ED unit coordinator (i.e. unit secretary) o   ED nurses x2 o   ED patient care technician o   ED phlebotomist x1-2 o   ED pharmacist as available o   ED X-ray technician • Code Sepsis electronic order entry: Code Sepsis order sets for diagnostic evaluation and antibiotic treatment will be constructed and activated at the intervention ED's electronic medical record with the beginning of study Phase #2. Order sets will help speed up diagnostic testing and treatment initiation, aid care standardization, and facilitate Code Sepsis event tracking and data collection.   • Code Sepsis clinical team training: With active support from intervention hospital clinical leadership as well as Intermountain's system-wide ED leadership team, the Code Sepsis ED Implementation Team will provide clinical staff in the implementation ED with training on the Code Sepsis protocol during the months prior to study Phase #2. Primary training will include distribution of instructional materials, direct education at clinical staff meetings, targeted in-person education, and in situ simulation. Primary training will complete early in study Phase #2, with consolidation training, protocol reminders, physician detailing, and targeted clinician reeducation continuing through study Phase #3.    
Code Sepsis I protocol Version 3.0 
 18 6. DATA COLLECTION AND VARIABLES  Core analyses will employ data collected during routine clinical care and hospital operations. There will be no direct patient contact for collection of identifiable data or specimens.  6.1 Data Collection Intermountain’s Enterprise Data Warehouse (EDW) is a centrally-managed, well-curated, and accessible database linking system-wide clinical, billing, laboratory, and other data.31  Eligible patient subjects will be identified by project data managers from EDW data, who will generate a dataset specific to the proposed study by linking EDW data to additional data abstracted from the electronic health record. Manual chart review and direct queries to bedside clinicians will be employed as needed to supplement electronically-available data. This encounter level data will be linked to additional data on hospital characteristics, physician and nurse staffing. Long-term mortality data will be obtained through a preexisting linkage to Utah state death records and/or the federal Social Security Death Index. Encounter data will be linked to data on race, ethnicity, and hospital admissions (admit date, type, diagnoses, and costs) stored in the Utah Population Databank. We will employ a preexisting linkage to Utah State death records and the federal Social Security Death Index for mortality ascertainment.   6.2 Anonymous Data Collection For Protocol Development and During Live Code Sepsis Activation The study team will receive notification of Code Sepsis activations. As part of the study operational process, ED clinical leadership and study personnel will directly observe a convenience sample of these events to anonymously record protocol parameters, including team composition and process completion times. In addition, a convenience sample of intervention hospital patients (<10) with sepsis may be observed during the pre-Code Sepsis implementation phase to understand care processes involved in sepsis care. No identifying information about the patient or clinical team will be recorded.  6.3 Active Follow-Up for Patients Undergoing Code Sepsis Via the electronic medical record, a member of the study team will actively monitor Code Sepsis activation patients every 1-3 days until hospital day #7. There will be no direct patient contact.  6.4 Protected Health Information Protected health information including subject encounter codes, medical record numbers, birthdates, encounter event date and times, address, and social security number will be collected during the electronic query to allow manual chart abstraction and manual review of electronic record for data completion and verification.  6.5 Variables/data elements • Patient medical record number(s) • Patient encounter ID code • Hospital/facility • Date of birth • Age • Sex • Race 
Code Sepsis I protocol Version 3.0 
 19 • Ethnicity • Marital status • Preferred language • Insurance status/type • Address/zip code (for determination of residence at a nursing facility or other long-term care facility and estimation of socioeconomic status) • Social Security Number (to assist matching of encounter data to Social Security Death Index and Utah state death records) • ED disposition • Hospital disposition • Date/time of all events related to ED visit and hospitalization (e.g. ED arrival & departure, hospital admission & discharge) • Date/time antibiotics administered • Antibiotic utilization • APACHE II score • APACHE IV score • Acute physiology score • Charlson index • Elixhauser index • SOFA score • Baseline SOFA score over preceding 10 years • Source of admission (e.g. home, SNF, LTAC, outside hospital) • Source of infection • Clinician infection determination, patient illness severity, sepsis status, and agreement with Code Sepsis activation • Sepsis presence/absence • Culture results • Admission diagnosis • Mode of arrival to ED • ED triage data including triage acuity score • Resident involvement in ED care • Results of all laboratory testing • Date/time of all laboratory testing  • ED length of stay • ED vital signs • ED medications • ED interventions/procedures • Date/time, elapsed time, and type of ED events including provider interaction, room placement, disposition • Date/time of diagnostic testing, vasopressor initiation and other interventions, and management • Date/time of interventions • Date/time of blood or body fluid cultures • Discharge diagnosis and procedure codes  • Billing diagnosis and procedure codes • Diagnosis-related group • Hospital length of stay 
Code Sepsis I protocol Version 3.0 
 20 • In-hospital mortality • Long-term mortality (e.g. 30d, 90d and 1y mortality) • Healthcare charges • ED patient census • Number of ED beds • ED patient flow (including counts of patient arrivals, boarding, and admissions) • Attending physician ED staffing • Nurse staffing • Trauma registration status • Allergies • Adverse drug reaction events and date/time • Code Sepsis team activation (Y/N) • Code Sepsis activation date/time  • Code Sepsis care process completion date/times • Code Sepsis team function • Code Sepsis team composition (by role) • Code Sepsis process adherence  6.6 Data Management Data analysts and research coordinators will collect data and record it in a custom-designed computer database. Data abstraction from electronic medical records will employ either standardized paper data sheets or a custom-designed interface maintained within Intermountain’s secure Research Electronic Data Capture (REDCap) platform.32 Outside REDCap, all study data will be kept in a protected database on a protected computer. Each subject will be assigned a study identification number, and we will maintain minimal patient identifiers. Data for analysis will use study ID codes for patient subjects. Shared or presented data will be in anonymized or aggregate format such that individual patient subjects cannot be reidentified. Any hard copy case report forms will only include study identification numbers, and will be stored in a locked file cabinet.    
Code Sepsis I protocol Version 3.0 
 21 7. DATA ANALYSIS   7.1 Introduction to Quasi-Experimental Analysis This study will measure the effect of implementing a team-based Code Sepsis protocol for ED sepsis patients by comparing risk-adjusted process and patient-centered outcomes before versus after protocol implementation at a single hospital. Results from simple pre/post analyses, however, may be subject to misinterpretation due to secular trends (changes in the measured outcomes over time not attributable to the study intervention). Analyses of Aim III primary and secondary outcomes will therefore employ quasi-experimental methods to eliminate confounding due to secular trends when estimating the effect of Code Sepsis implementation on outcomes. More complex methods of quasi-experimental analysis includes interrupted time series and regression discontinuity, but are analogous to the relatively simpler approach called difference-in-difference analysis (Figure 4).33 Difference-in-difference analysis uses multivariable linear regression to compare the adjusted mean door-to-antibiotic time (primary outcome) at the intervention hospital pre- versus post-implementation of the Code Sepsis protocol using the measured change at non-intervention hospitals to control for pre-/post-intervention changes not attributable to protocol implementation.34 This model tests the difference in intervention ED versus non-intervention EDs’ differences in outcome before versus after the Code Sepsis implementation (Figures 4-5). The b3 parameter from the regression model depicted in Figure 5 provides the adjusted difference-in-differences estimate and significance tests for the influence of the Code Sepsis intervention on the outcome of interest.   7.2 Multivariable models Multivariable models will be adjusted for demographic and clinical parameters with known or plausible associations with both door-to-antibiotic time and treatment hospital, presentation before or after Code Sepsis implementation, and/or Code Sepsis activation. Evaluation of secondary outcomes will employ an analogous approach using multivariable linear, Poisson, or logistic regression as appropriate. Repeating the quasi-experimental analysis for the primary and key secondary outcomes after stratification (rather than adjustment) by (1) sex and (2) hypotension present versus absent on ED arrival will allow evaluation of whether these patient characteristics modify the effects of Code Sepsis implementation. In order to measure how the Code Sepsis protocol influences the care of its core target population, we will perform analyses comparing selected outcomes among the subset of patients who have ED triage data suggesting a strong possibility of sepsis. Outcomes to be evaluated in the sensitivity analyses will include door-to-antibiotic time, antibiotic treatment fraction, and antibiotic treatment spectrum.  7.3 Sample size/power analysis Using 2013 to 2017 data from our study hospitals, we estimated conservatively that the intervention ED provides care for 1,650 sepsis patients annually (approximately 4.5 sepsis patients per day) and the  Figure 4. Difference-in-differences analysis  𝒀𝒊=𝛽"ERA#+𝛽$HOSP+𝜷𝟑𝐄𝐑𝐀𝒊×𝐇𝐎𝐒𝐏𝒊+𝛽&(Z#) Figure 5. Simplified difference-in-differences equation. Yi is the door-to-antibiotic time for patient i, HOSP and ERA are, respectively, indicator variables for care at the intervention hospital or an ED arrival date after Code Sepsis implementation, and Z is a vector of covariates. b3 is the coefficient of interest. 

Code Sepsis I protocol Version 3.0 
 22 control EDs together care for a total of 2,200 sepsis patients annually (approximately 6 sepsis patients per day). Based on the design and our pilot testing of the Code Sepsis protocol, a very conservative estimate of door-to-antibiotic time for patients who receive antibiotics after evaluation under the Code Sepsis protocol is 50 minutes. By comparison, our preliminary data from 2013 to 2017 indicates current mean (SD) door-to-antibiotic time for ED sepsis patients is 170 (±75) minutes and that only 5% of patients currently receive antibiotics within 1 hour of ED arrival. Assuming (again conservatively) that the Code Sepsis protocol is activated for 30% of sepsis patients treated in the intervention ED during the full implementation phase (study phase #3), we will have 90% power to detect a difference-in-differences change of 16 minutes or more in door-to-antibiotic time associated with Code Sepsis implementation, with the measurement population being all ED sepsis patients. Power calculations employed Monte Carlo simulations, for which technical details are available upon request.   
Code Sepsis I protocol Version 3.0 
 23 8. RISK ASSESSMENT This study involves a before-and-after analysis of the effects of reorganizing standard ED care for sepsis. Patient care will be studied under two designs for standard sepsis care.  8.1 Potential Risks 8.1.1 Risk of confidentiality breach Potential consequences of a breach of confidentiality to the subject could include identify loss of privacy, medicolegal liability, theft, embarrassment, or harassment.  8.1.2 Risks for control group patients Aside from issues discussed above, there are no foreseeable risks for ED patients receiving care at a non-intervention hospital or at the intervention hospital during study phase #1 and #2. Sepsis patients arriving to control hospitals will receive standard care throughout the study.   8.1.3. Risks to patients exposed to the Code Sepsis protocol  Patients presenting to the intervention hospital during phases #2 and 3 (run-in implementation and full implementation) will be exposed to and may receive care using the “Code Sepsis” version of standard care. The Code Sepsis protocol is designed to accelerate evaluation, testing, and treatments that the patient would have eventually received under now current standard care. The Code Sepsis intervention is therefore expected to pose no more than minimal risks to ED patients exposed to the protocol, including specifically sepsis patients for whom the Code Sepsis protocol is activated. The potential risks to subjects due to this protocol include:  1) Adverse drug reactions or antibiotic-associated infections related to unnecessary or overtreatment antibiotic treatment with prespecified regimens. 2) Delay in diagnosis of non-infectious problems due to focus on sepsis or infection related to Code Sepsis activation. 3) Delay in care related to resource allocation away from non-Code Sepsis patients without sepsis (bystanders without sepsis).  4) For sepsis patients for whom the Code Sepsis protocol is not activated (i.e. bystanders with sepsis), delay in care related to lower index of suspicion for sepsis leading to delayed diagnosis or resource allocation away from these patients.    8.2 Alternatives to Participation There are no alternatives to participation in this pragmatic before/after implementation research study.  8.3 Minimization of Risks Federal regulations at 45 CFR 46.111(a)(1) require that risks to subjects are minimized by using procedures which are consistent with sound research design. We will review the electronic medical record of all Code Sepsis activations for potential adverse effects related to study procedures. This will include review of standardized Code Sepsis documentation incorporated into clinical care as part of the care redesign. While there are no foreseeable effects of data collection on the care of patients who receive standard care at the control hospitals (all study phases) or during the pre-intervention phase at Intermountain Medical Center, monitoring of aggregate data quality will include all hospitals and study phases. As necessary, after consultation with the Independent Safety Monitor, study procedures (including the Code Sepsis protocol) will be adjusted or even halted if important adverse effects are 
Code Sepsis I protocol Version 3.0 
 24 identified. There are several specific elements of study design inherent in the present protocol that meet this human subject protection requirement.   8.3.1 Protections against invasion of privacy or breach of confidentiality Protection of subject identity and prevention of unintentional release of protected information is of paramount importance to the research team.  • Data storage and transfer: Data will be maintained in password-protected, encrypted research servers, REDCap (a secure, HIPAA-compliant system), or password-protected, encrypted computers. Patient identifiers for prehospital data linkage in Aim I will be provided in secure, encrypted electronic format to Department of Health staff for identification of ambulance patient care reports. Matched records will be returned in secure, encrypted electronic format. All devices will have been approved by Intermountain Healthcare or (during matching of ED data to prehospital data) the Utah Department of Health for use with clinical and research data. Both Intermountain and the State of Utah deploy comprehensive information technology support systems to maintain and regularly update computer systems and maintain physical and electronic safeguards for data management. Any paper case report forms will only include study identification numbers, and will be stored in a locked file cabinet. Datasets used for statistical analyses will be deidentified. • Data access: Only the PI and the study team will have access to identifying information. All individuals with access to identifiable data will have all necessary human subjects training, including Good Clinical Practice training as required by NIH policy for applicable study team members involved in the clinical trial proposed.  • Training: All study personnel will maintain appropriate training in human subjects research and data protection. The PI, primary mentor, and study staff responsible for study coordination, data collection, and data management of the associated clinical trial will maintain Good Clinical Practice training as per NIH policy (NOT-OD-16-148).  8.3.2 Incidental findings Data review and analysis will use only data collected as part of routine clinical care and operations. We therefore do not expect identification of incidental findings relevant to patient care.  8.3.3 Protection against medicolegal risk Data on subjects studied in the proposed aims will be kept confidential in accordance with applicable laws and statues.   8.3.4 Optimization of Code Sepsis targeting  Optimization of team activation mechanism during phase #2 of Aim III (intervention run-in and optimization) will help maximize false positive and minimize false negative team activations.   8.3.4 Protections against overtreatment and anchoring bias Physicians and other providers will be educated intensively about the protocol, with particular emphasis on the corresponding concepts that (1) a sepsis team activation does not establish a sepsis diagnosis and (2) that the sepsis prediction tool was specifically not designed to capture all patients with sepsis and that, as a consequence, many patients with sepsis will not trigger a Code Sepsis.   
Code Sepsis I protocol Version 3.0 
 25 8.3.5 Protections against overtreatment and adverse drug reactions Part of this redesign of standard care is incorporation of both direct pharmacist involvement in the Code Sepsis team and antibiotic stewardship monitoring of antibiotic-treated Code Sepsis patients to reduce antibiotic overtreatment. Pharmacist involvement will also help minimize the risk of preventable adverse drug or allergic reactions.   8.4 Potential Benefits of the Proposed Research to Human Subjects and Others This study has the potential to generate important findings for patients with sepsis and their treating clinicians, including methods to identify sepsis patients at ED triage or in the prehospital setting.  Sepsis patients treated in the intervention ED after implementation of the full Code Sepsis protocol could receive faster evaluation, diagnosis, and treatment initiation, leading to improved patient outcomes. The risks to patient confidentiality and the risks for adverse drug reactions appear substantially less than the potential benefit to sepsis patient subjects and the important knowledge gained about delivery of ED sepsis care.  8.5 Importance of the Knowledge to be Gained Patients with sepsis —a syndrome defined by infection associated with acute organ dysfunction — have high mortality. This syndrome is also common, affecting nearly 3% of ED patients in our data. Early antibiotic initiation improves sepsis outcomes, but many ED patients do not receive timely antibiotics. The overall hypothesis of this phase 2a study is that reorganizing standard ED sepsis care around multidisciplinary “Code Sepsis” teams activated prior to or immediately upon patients’ ED arrival will reduce door-to-antibiotic times. Aim III of this proposal will determine whether the Code Sepsis protocol is feasible, safe, and effective at decreasing door-to-antibiotic time. Data from human subjects are also necessary to validate triage- or prehospital-based sepsis prediction models that can be customized by users planning sepsis screening, intensive resource mobilization (as is planned here) for sepsis care, or to aid risk/benefit decisions for sepsis treatments with more than minimal risks (Aim I) and to understand how practice patterns or systems of care may be optimized to accelerate time-dependent treatment while minimizing unintended consequences (Aim II). The no-more-than-minimal risks to subjects from observational research (Aims I and IIA), interviews (Aim IIB), or systematically reorganizing sepsis care to accelerate evaluations and treatments patients would receive anyway under current standard care (Aim III) are acceptable in the context of the important knowledge to be gained to improve care for the common and deadly sepsis syndrome.   
Code Sepsis I protocol Version 3.0 
 26 9. HUMAN SUBJECTS We will prospectively assess the effect of a system-level intervention on the organization of ED sepsis care using an augmented pre-/post-intervention design. In the post-intervention period, the studied intervention — early activation of ED teams for patients likely to have sepsis — will be adopted as standard care at Intermountain Medical Center. As such, no patients arriving to any ED during the pre-intervention or to a non-intervention control ED will be exposed to the intervention. Conversely, all patients arriving to the Intermountain Medical Center ED in the post-intervention phase will be exposed to the intervention.   9.1 Selection of Subjects Federal regulations at 45 CFR 46(a)(3) require the equitable selection of subjects. All eligible patients will be enrolled. Study exclusion criteria neither unjustly exclude classes of individuals from participation in the research nor unjustly include classes of individuals from participation in the research. Hence, the recruitment of subjects conforms to the principle of distributive justice.   9.2 Waiver of Informed Consent and HIPAA Authorization To allow analysis of patient outcomes in all patients during both the pre- and post-intervention phases and to facilitate future research through creation of a research registry, we will request a waiver of informed consent and HIPAA authorization based on the following criteria as per 45 CFR 46.116(d) and the HIPAA Privacy Rule.  9.2.1 Research and registry involve no more than minimal risk  Acceptance is widespread for protocols using pre-arrival notification to activate ED teams for the treatment of other critical illnesses where time-to-treatment determines outcomes. Since the tested exposure will be incorporated into ED care processes as standard care, and will merely accelerate evaluation, testing, and treatment sepsis patients would receive during current (pre-intervention) standard care, patients will overall experience only the risks associated with standard ED clinical care. Research and registry creation involve no direct contact between the study team and patients, only review of records routinely collected for administration and medical care. For a small number of subjects, there will be anonymized monitoring of ED operations in the form of non-interactive observation of Code Sepsis protocol completion involving collection of anonymous data, which would be standard during implementation of any approach to improving standard ED care.   9.2.2 No adverse effects on the rights and welfare of participants Exposure to standard care in the form of the Code Sepsis protocol and research team abstraction of data routinely collected in the course of clinical care should have no influence on the welfare of study subjects. Analysis and registry storage of data recorded as part of routine clinical care and operations should have no influence on the welfare of study subjects. Because risk is minimal given this design, the waiver of consent and authorization will not adversely affect the rights or welfare of subjects.  9.2.3 The research and registry could not practicably be carried out without waiver of informed consent Given the large number of eligible patient subjects (up to 530,000, including approximately 9,450 patients with sepsis in the primary analysis cohort), the research and registry could not practicably be carried out without the waiver of consent. The sample size for this chart review is large enough that including only those data for which consent could be obtained would prohibit conclusions to be drawn 
Code Sepsis I protocol Version 3.0 
 27 and would compromise the scientific validity of the study, as a large proportion of the data would be eliminated if obtaining consent were a requirement. Obtaining consent would also preclude rapid initiation of the Code Sepsis protocol and rapid antibiotic initiation. The subjects whose records will be reviewed will not be followed beyond their hospitalization (except for routine use of data on long-term mortality obtained via existing linkages) and would be mostly lost to follow up. The proportion of subjects who have relocated or have passed away will likely be a significant percentage of the subject population, and so the research results would not be meaningful and would lose statistical power if obtaining consent were a requirement.  9.2.4 Information on the Code Sepsis protocol and study will be available to all ED patients We will make available patient information sheets describing the Code Sepsis protocol in the intervention emergency department (e.g. lobby, patient information stations, and on request). It is otherwise not possible to provide patient subjects with information about the study as there is no feasible mechanism by which to notify subjects, attempting to do so would substantially increase the risk of a confidentiality breach, and because the information that is found will have no impact on subjects’ clinical care.  9.2.5 The minimal necessary amount of protected information will be obtained Only data necessary for the completion of the study will be collected. The patient ID, encounter ID, social security number, address, and date of birth are necessary to allow data linkage, identification of the specific patient encounter for supplemental data abstraction. Event date/times are necessary for care process and outcome measurement, including calculation of the elapsed time related to various patient management actions include the primary outcome. Identifiers will maintained in the registry to facilitate future research.  9.2.6 All data, including PHI, will be securely guarded from improper disclosure  High-level safeguards will be in place to protect subject identity and confidential data, including in data maintained in the research registry. The study and registry data will be kept on encrypted, password-protected computers. These computers are routinely used for storage of patient data and research data including subject identifiers. The data will only be accessible to members of the research team, and all members of the research team have completed Human Subjects Protections and understand the importance of protecting subject privacy and confidentiality. No PHI will be recorded on the CRFs for the study dataset. Protected health information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, for other research as approved by an IRB, or for other research for which the use or disclosure of protected health information would be permitted by under applicable regulations. Minimal identifiers will be maintained linked to the data. Maintaining minimal identifiers linked to the data is necessary to allow (1) manual abstraction of additional data from the electronic medical record and (2) potential future linkage – with IRB approval -- of the data to additional datasets. No individual subject data will be presented in any presentation, publication or report related to this research. Data will be presented only in anonymized or aggregate or as results of statistical analyses and will not include any individual-level data that could be traced to a particular subject.     
Code Sepsis I protocol Version 3.0 
 28 10. MONITORING AND SAFETY REPORTING  On the basis of established precedents in implementation research, using toolkits supplied by NIH institutes and the University of Washington’s CTSA-supported Institute for Translational Health Sciences and in consultation with the Intermountain Institutional Review Board (IRB) and National Institutes of Health (NIH) staff, we believe the proposed clinical trial represents no more than minimal risk to exposed patients. The study will thus be overseen by an Independent Safety Monitor (ISM), a practicing ICU physician with extensive experience performing clinical trials but not affiliated with the current trial.  10.1 Potential Risks and Benefits for Participants • Potential risks: The risk level associated with this study is estimated to be no more than minimal, since the studied intervention — prehospital activation of ED-based Code Sepsis teams — will be adopted as standard care and is designed to accelerate evaluation, testing, and treatments that the patient would have eventually received under current standard care. While the efficient coordination of therapies is novel and likely to improve care overall, we will monitor for the possibility of effects potentially relevant to faster antibiotic therapy, specifically receipt of antibiotics to which the patient is known to be allergic. This possibility is protected against through inclusion of a pharmacist in the Code Sepsis team. Other risks are also minimal and related to loss of confidentiality of data. • Potential benefits: The potential benefits to study subjects with sepsis treated in the intervention ED after implementation of the full Code Sepsis protocol include faster evaluation, diagnosis, and treatment initiation leading to improved patient outcomes.  10.2 Adverse Event and Serious Adverse Event Collection 10.2.1 Adverse event A clinical trial adverse event is any untoward medical event associated with the use of the study procedure, whether or not it is considered related to a drug or study procedure. After Code Sepsis intervention, adverse events related or possibly related to study procedures must be evaluated by the PI. The PI, with assistance from study co-investigators as needed, will assess whether there is a reasonable possibility that the study procedure caused the event, based on the criteria below. Investigators will also consider whether the event is unanticipated or unexplained given the patient’s clinical course, previous medical conditions, and concomitant medications. If the severe adverse event is judged to be reportable, as outlined below, then the investigator will report to the ISM and IRB his assessment of the potential relatedness of each adverse event to protocol procedure.  The study uses the following AE attribution scale: • Definitely Related: The event follows: a) A reasonable, temporal sequence from a study procedure; and b) Cannot be explained by the known characteristics of the patient’s clinical state or other therapies; and c) Evaluation of the patient’s clinical state indicates to the investigator that the experience is definitely related to study procedures.  • Probably or Possibly Related: The event should be assessed following the same criteria for “Definitely Associated”. If in the investigator’s opinion at least one or more of the criteria are not present, then “probably” or “possibly” associated should be selected.  • Probably Not Related: The event occurred while the patient was on the study but can reasonably be explained by the known characteristics of the patient’s clinical state or other therapies.  
Code Sepsis I protocol Version 3.0 
 29 • Definitely Not Related: The event is definitely produced by the patient’s clinical state or by other modes of therapy administered to the patient. • Uncertain Relationship: The event does not meet any of the criteria previously outlined.  10.2.2 Serious Adverse Event (SAE) An SAE is any AE that results in any of the following outcomes: • Death • A life-threatening experience (that is, immediate risk of dying) • Event requiring prolongation of existing hospitalization. As per http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm: Report if admission to the hospital or prolongation of hospitalization was a result of the adverse event. Emergency room visits that do not result in admission to the hospital should be evaluated for one of the other serious outcomes (e.g., life-threatening; required intervention to prevent permanent impairment or damage; other serious medically important event). • Persistent or significant disability/incapacity. As per http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm: Report if the adverse event resulted in a substantial disruption of a person's ability to conduct normal life functions, i.e., the adverse event resulted in a significant, persistent or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities and/or quality of life. • Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious adverse events when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.   10.2.3 Adverse event monitoring The PI will review potential adverse events monthly for patients for whom the Code Sepsis protocol was activated during the patient’s ED visit. The PI will also review within 72 hours of identification any potential anaphylaxis cases occurring within 24 hours of ED antibiotic initiation in Code Sepsis patients. Adverse events will be monitored via review of the medical record for the first 3 days after Code Sepsis activation or until hospital discharge, whichever occurs first, regardless of the investigator's opinion of causation. Thereafter, serious adverse events are not required to be collected unless routine clinical care monitoring or the PI believes that the event was possibly, probably, or definitely to the Code Sepsis protocol.   10.3 Adverse Event and Serious Adverse Event Reporting We emphasize in AE reporting for this study that the intervention under study is an expedited bundling of established elements of clinical care. Study-specific clinical outcomes of sepsis and ED clinical care are exempt from adverse event reporting unless the investigator deems the event to be related to the administration of study drug or the conduct of study procedures (or of uncertain relationship). The following are examples of events that will be considered routinely recorded clinical outcomes: • Death not related to study procedures.  • Adverse drug reaction (excluding anaphylaxis associated with antibiotic administration) not related to study procedures • Secondary and healthcare associated infections • Persistent or progressive organ failure 
Code Sepsis I protocol Version 3.0 
 30 • Prolonged hospitalization  The PI will report to the ISM within 72 hours of identification all AEs that are serious and possibly, probably, or definitely related to study procedure (or of uncertain relationship) or are unexpected. If the ISM concurs with the PI’s assessment, the AE will be reported to the IRB within 7 business days. Other AEs will be reviewed by the PI on a monthly basis and reported in aggregate to the ISM on a quarterly basis. A summary report on all adverse events will be submitted to the IRB during annual recertification as per IRB guidelines. Good Clinical Practice will be followed for conduct of the study.   10.4 Interim Analysis There will be no interim analyses.  10.5 Data and Safety Monitoring Given that this study is using pre-post method to study implementation of a method to deliver clinical standard-of-care therapies in a more efficient, expeditious, and coordinated manner, the safety monitoring plan will be implemented with the use of an Independent Safety Monitor (ISM). The ISM will monitor participant safety, evaluate the progress of the study, review procedures for maintaining the confidentiality of data, and monitor the quality of data collection, management, and analyses. The PI and study personnel will provide all necessary and requested reports to the ISM in a timely manner. The ISM will have full capacity to end the study at her/his discretion if there is an important safety signal, according to a safety monitoring charter that will be finalized in consultation with NIH and the ISM before study launch. Notably, given that the “intervention” in this trial is a non-randomized implementation of a bundle of timely care for sepsis treatment, the safety monitoring plan will focus on monitoring the Code Sepsis activations. The PI will be responsible for ensuring participants’ safety and that the study is conducted according to the IRB-approved research plan on a daily basis.   10.5.1 Safety Monitoring Procedures 1. Since this research examines implementation of a method to deliver clinical standard-of-care therapies in a more efficient, expeditious, and coordinated manner, the foundation for safety monitoring for this study is the routine quality assurance monitoring of the study hospital’s Emergency Department. This quality assurance activity includes review of incident reports for clinical adverse events. The ED physician who serves as site medical director and currently has lead responsibility for monitoring of care quality and safety in each study ED. The study team will be in monthly contact via telephone or email with the ED medical director overseeing quality assurance efforts at the intervention hospital to identify potential concerns possibly, probably, or definitely related to Code Sepsis implementation. If necessary, comparisons to control hospital EDs will be performed on the basis of reports from their medical directors. 2. Specific to study procedures, all Code Sepsis activations will be individually evaluated. The PI will review all Code Sepsis activations on a monthly basis. AEs will be reported to the ISM in aggregate on a quarterly basis. The PI will report to the ISM within 72 hours of identification all AEs that are serious and possibly, probably, or definitely related to study procedure (or of uncertain relationship) or are unexpected. The ISM and PI together will reach consensus on the ultimate characterization of these possible serious adverse events (SAEs). If disagreement persists after discussion between the ISM and PI, the ISM will make the final decision about the status of the possible SAE. SAEs will be reported to the IRB within 7 business days.  3. If required by NIH or other governing bodies, or based on issues observed during trial conduct, we will convene a Data Safety Monitoring Board (DSMB) of clinical experts and members with 
Code Sepsis I protocol Version 3.0 
 31 expertise in implementation trials with assistance from the Utah Center for Clinical and Translational Science.  10.5.2 Enrollment, procedure, regulatory, and data quality monitoring Our data monitoring plan will include 1. Review of accrued data at monthly study team meetings 2. Review of data safety and interim data analysis performed by the independent safety monitor 3. Semi-annual audits of study materials by the Intermountain PCCM regulatory affairs group 4. An annual review performed by the Intermountain Healthcare IRB  Careful monitoring of the data collection, regulatory adherence, data quality, and study procedures will help to protect the safety of study subjects, the quality of data, and the integrity of the study. The PI or study staff will review all data collection on an ongoing basis for data completeness and accuracy as well as protocol compliance. Data verification for key demographic, exposure, and outcome parameters will be performed on an ongoing basis for a random 5% of all Code Sepsis patients. This will occur on the basis of data reabstraction by someone other than the individual who originally collecting the data or by blinded duplicate data entry. The results of the ongoing data review will be incorporated into each review with the ISM. A statement reflecting the results of the ongoing data review will be incorporated into the annual report for the IRB.   10.5.3 Frequency of data and safety monitoring  The PI and study team will review data quality and adverse event reports monthly and meet with the ISM quarterly, either in-person or by teleconference call, to review study progress, data quality, and participants’ safety. A summary report on all adverse events and data quality will be submitted to the IRB during annual recertification as per IRB guidelines.  10.5.4 Independent safety monitor identify and affiliation The following individual has agreed to serve as the independent safety monitor for the study: Eliotte Hirshberg, MD, MS Division of Pulmonary & Critical Care Medicine, Intermountain Medical Center Associate Professor of Medicine, University of Utah School of Medicine  10.5.5 Conflict of interest for independent safety monitor The ISM will have no direct involvement with the study investigators or intervention. The independent safety monitor will sign a Conflict of Interest Statement which includes current affiliations, if any, with pharmaceutical and biotechnology companies (e.g., stockholder, consultant), and any other relationship that could be perceived as a conflict of interest related to the study and/or associated with commercial interests pertinent to study objectives.  10.5.6 Independent safety monitor responsibilities • Review and approve the research protocol and plans for data safety and monitoring; • Evaluate the progress of the trial, including periodic assessments of data quality and timeliness, recruitment, accrual, participant risk versus benefit, and other factors that can affect study outcome; 
Code Sepsis I protocol Version 3.0 
 32 • Consider factors external to the study when relevant information becomes available, such as scientific or therapeutic developments that may have an impact on the safety of the participants or the ethics of the trial; • Review study performance, make recommendations and assist in the resolution of problems reported by the PI; • Protect the safety of the study participants; • Make recommendations to the PI concerning continuation, termination or other modifications of the trial based on the observed adverse effects of the treatment under study; • Ensure the confidentiality of the study data and the results of monitoring; and, • Assist the IRB by commenting on any concerns related to study conduct, enrollment, sample size, and/or data collection.  10.6 Confidentiality During Adverse Event Reporting  AE reports and annual summaries will not include subject- or group-identifiable material. Each report will only include the identification code. Data will be presented in a blinded manner during any open sessions involving the ISM. At meetings with the ISM or in IRB reports, data and discussion are confidential. Participant identities will not be known to the ISM or to the IRB.    
Code Sepsis I protocol Version 3.0 
 33 11. BIBLIOGRAPHY  1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.  2. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167–74.  3. Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013: Statistical Brief #204. Healthcare Cost and Utilization Project. 2016. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.jsp.: Accessed July 6, 2017. 4. Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308–16.  5. Peltan ID, Mitchell KH, Rudd KE, et al. Physician variation in time to antimicrobial treatment for septic patients presenting to the emergency department. Crit Care Med. 2017;45:1011–8.  6. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med. 2001;345:1368–77.  7. ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. New Engl J Med. 2014;370:1683–93.  8. ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, et al. Goal-directed resuscitation for patients with early septic shock. New Engl J Med. 2014;371:1496–506.  9. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.  10. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–53.  11. Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196:856–63.  12. Seymour CW, New York State Office of Quality and Patient Safety, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. New Engl J Med. 2017;376:2235–44.  13. Peltan ID, Brown SM, Bledsoe JR, et al. Emergency department door-to-antibiotic time and long-term mortality in sepsis. Chest. 2019.  14. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486–552.  15. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44:925–8.  16. Peltan ID, Mitchell KH, Rudd KE, et al. Prehospital care and emergency department door-to-antibiotic time in sepsis. Ann Am Thorac Soc. 2018;15:1443–50.  17. Peltan ID, Bledsoe JR, Oniki TA, et al. ED crowding is associated with delayed antibiotics for sepsis. Ann Emerg Med. 2018.  18. MacKenzie EJ, Rivara FP, Jurkovich GJ, et al. A national evaluation of the effect of trauma-center care on mortality. New Engl J Med. 2006;354:366–78.  19. Kim SK, Lee SY, Bae HJ, et al. Pre-hospital notification reduced the door-to-needle time for IV tPA in acute ischaemic stroke. Eur J Neurol. 2009;16:1331–5.  20. Mosley I, Nicol M, Donnan G, Patrick I, Kerr F, Dewey H. The impact of ambulance practice on 
Code Sepsis I protocol Version 3.0 
 34 acute stroke care. Stroke. 2007;38:2765–70.  21. Pedersen SH, Galatius S, Hansen PR, et al. Field triage reduces treatment delay and improves long-term clinical outcome in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2009;54:2296–302.  22. Sejersten M, Sillesen M, Hansen PR, et al. Effect on treatment delay of prehospital teletransmission of 12-lead electrocardiogram to a cardiologist for immediate triage and direct referral of patients with ST-segment elevation acute myocardial infarction to primary percutaneous coronary intervention. Am J Cardiol. 2008;101:941–6.  23. Seymour CW, Rea TD, Kahn JM, Walkey AJ, Yealy DM, Angus DC. Severe sepsis in pre-hospital emergency care: analysis of incidence, care, and outcome. Am J Respir Crit Care Med. 2012;186:1264–71.  24. Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med. 2008;149:29–32.  25. Singer M. Antibiotics for sepsis: Does each hour really count, or is it incestuous amplification? Am J Respir Crit Care Med. 2017;196:800–2.  26. Klompas M, Calandra T, Singer M. Antibiotics for sepsis — Finding the equilibrium. JAMA. 2018;320:1433–4.  27. Croskerry P. From mindless to mindful practice--cognitive bias and clinical decision making. New Engl J Med. 2013;368:2445–8.  28. Stenehjem E, Hersh AL, Sheng X, et al. Antibiotic use in small community hospitals. Clin Infect Dis. 2016;63:1273–80.  29. Call K, Donohue M, Fontaine G, et al. Care Process Model: Emergency Management of Acute Ischemic Stroke. Intermountain Healthcare. 2017. Available at: https://intermountainhealthcare.org/ext/Dcmnt?ncid=520500199.: Accessed October 27, 2018. 30. George P, Wisco DR, Gebel J, Uchino K, Newey CR. Nurses are as specific and are earlier in calling in-hospital stroke alerts compared to physicians. J Stroke Cerebrovasc Dis. 2017;26:917–21.  31. Clayton PD, Narus SP, Huff SM, et al. Building a comprehensive clinical information system from components: the approach at Intermountain Health Care. Methods Inf Med. 2003;42:1–7.  32. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.  33. Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA. 2014;312:2401–2.  34. Peltan ID, Brown CE, Burke AK, Chow EJ, Rowhani-Rahbar A, Crull MR. The July Effect on maternal peripartum complications before and after resident duty hour reform: a population-based retrospective cohort study. Am J Perinatol. Thieme Medical Publishers, 2017;34:818–25.     
Code Sepsis I protocol Version 3.0 
 35 APPENDIX A — Eligible IV and IV-equivalent antibiotics  Antibiotic Brand/alternative name Eligible routes Acyclovir Zovirax IV Amikacin Amikin IV Amphotericin Amphotec, Ambisome IV Ampicillin Principen IV Ampicillin/sulbactam Unasyn IV Anidulafungin Eraxis IV Azithromycin Zithromax, Zmax, Sumamed IV Aztreonam Azactam IV Caspofungin Cancidas IV Cefazolin Ancef IV Cefdericol Fetroja IV Cefepime Maxipime IV Cefoperazone Cefobid IV Cefotaxime Claforan IV Cefotetan Cefotan IV Cefoxitin Mefoxin IV Ceftaroline Teflaro IV Ceftazidime Fortaz IV Ceftazidime/avibactam Avycaz IV Ceftizoxime Cefizox IV Ceftolozane/tazobactam Zerbaxa, Ceftolozane IV Ceftriaxone Rocephin IV Cefuroxime Ceftin, Zinacef IV Chloramphenicol Chloromycetin IV Cidofovir Vistide IV Ciprofloxacin Cipro, Ciprobay, Ciproxin IV Clindamycin Cleocin IV Colistin Colymycin IV Dalbavancin Dalvance IV Daptomycin Cubicin IV Delafloxacin Baxdela IV Doripenem Doribax IV Doxycycline Doxychel, Vibramycin IV Eravacycline Xerava IV Ertapenem Invanz IV Erythromycin Erythocin, Erythroped IV Fidaxomycin Dificid PO Fluconazole Diflucan IV Ganciclovir Cytovene IV Gentamicin Garamycin IV Imipenem/cilastin Primaxin IV Isavuconazole Cresemba, Isavuconazonium IV Itraconazole Sporanox, Onmel IV Levofloxacin Levaquin IV Linezolid Zyvox IV 
Code Sepsis I protocol Version 3.0 
 36 Antibiotic Brand/alternative name Eligible routes Meropenem Merrem IV Meropenem/vaborbactam Vabomere IV Metronidazole Flagyl IV Micafungin Mycamine IV Minocycline Minocin IV Moxifloxacin Avelox IV Nafcillin Unipen, Nallpen IV Ofloxacin Floxin IV Omadadcycline Nuzyra, Paratek IV Oritavancin Orbactiv IV Oseltamavir Tamiflu PO Oxacillin Bastocillin IV Penicillin Penicillin V, Pencillin G, Pen VK, Bicillin, Veetids, Pentids, Permapen, Pfizerpen,  IV Peramavir Rapivab IV Piperacillin/tazobactam Zosyn IV Plazomicin Zemdri IV Posaconazole Noxafil IV Quinuopristin/dalfopristin Synercid IV Remdesivir Veklury IV Rifampin Rifadin IV Telavancin Vibativ IV Tetracycline Achromycin, Tetracyn, Sumycin, Tetrachel IV Ticarcillin/clavulanate Timentin IV Tidezolid Sivextro IV Tigecycline Tygacil IV Tobramycin   IV Trimethoprim/sulfamethoxazole Bactrim, Septra, Sulfatrim IV Vancomycin Vancocin PO Vancomycin Vancocin IV Voriconazole Vfend IV Zanamivir Relenza IV    
Code Sepsis I protocol Version 3.0 
 37 APPENDIX B — “Sepsis mimic” ICD codes B.1 Heart failure diagnosis codes1  ICD-9  ICD-10  Description  398.,91  I09.81  Rheumatic heart failure 402.01  I11.0  Hypertensive heart disease with heart failure 402.11  I11.0  Hypertensive heart disease with heart failure 402.91  I11.0  Hypertensive heart disease with heart failure 404.01  I13.0  Hypertensive heart/kidney dz w/heart failure, stage 1-4 CKD or unspec 404.03  I13.2  Hypertensive heart/kidney dz w/heart failure, stage 5 CKD or ESRD 404.11  I13.0  Hypertensive heart/kidney dz w/heart failure, stage 1-4 CKD or unspec 404.13  I13.2  Hypertensive heart/kidney dz w/heart failure, stage 5 CKD or ESRD 404.91  I13.0  Hypertensive heart/kidney dz w/heart failure, stage 1-4 CKD or unspec 404.93  I13.2  Hypertensive heart/kidney dz w/heart failure, stage 5 CKD or ESRD 428.0  I50.9  Heart failure, unspecified 428.1  I50.1  Left heart failure 428.20  I50.20  Unspecified systolic heart failure 428.21  I50.21  Acute systolic heart failure 428.22  I50.22  Chronic systolic heart failure 428.23  I50.23  Acute on chronic systolic heart failure 428.30  I50.30  Unspecified diastolic heart failure 428.31  I50.31  Acute diastolic heart failure 428.32  I50.32  Chronic diastolic heart failure 428.33  I50.33  Acute on chronic diastolic heart failure 428.40  I50.40  Unspecified combined systolic and diastolic heart failure 428.41  I50.41  Acute combined systolic and diastolic heart failure 428.42  I50.42  Chronic combined systolic and diastolic heart failure 428.43  I50.43  Acute on chronic combined systolic and diastolic heart failure 428.9  I50.810  Right heart failure, unspecified 428.9  I50.811  Acute right heart failure 428.9  I50.812  Chronic right heart failure 428.9  I50.813  Acute on chronic right heart failure 428.9  I50.814  Right heart failure due to left heart failure 428.9  I50.82  Biventricular heart failure 428.9  I50.83  High output heart failure 428.9  I50.84  End stage heart failure 428.9  I50.89  Other heart failure 428.9  I50.9  Heart failure, unspecified  Use only if below is primary diagnosis and one of above is second diagnosis 425.4  I42.0  Dilated cardiomyopathy 425.5  I42.6  Alcoholic cardiomyopathy 425.9  I42.7  Cardiomyopathy due to drug and external agent 425.9  I42.8  Other cardiomyopathy 425.9  I42.9  Cardiomyopathy, unspecified 425.8  I43  Cardiomyopathy in diseases classified celsewhere 429.83  I51.81  Takotsubo cardiomyopathy  1 Adapted from: Heart Failure CCW Chronic Conditions Algorithm. CMS Chronic Conditions Data Warehouse. 2018. Available at: https://www.ccwdata.org/web/guest/condition-categories.: Accessed 
Code Sepsis I protocol Version 3.0 
 38 February 13, 2019.  B.2 Pulmonary embolism diagnosis codes1,2  ICD-9 ICD-10 Description (from ICD-10)  415.11    Iatrogenic pulmonary embolism and infarction 415.13  I26.02 Saddle embolus of pulmonary artery with acute cor pulmonale 415.19  I26.09 Other pulmonary embolism with acute cor pulmonale 415.13  I26.92 Saddle embolus of pulmonary artery without acute cor pulmonale 415.19  I26.99 Other pulmonary embolism without acute cor pulmonale 673.20  O88.219 Thromboembolism in pregnancy, unspecified trimester 673.21  O83.22 Thromboembolism in childbirth 673.22  O88.22 Thromboembolism in childbirth 673.23  O83.211 Thromboembolism in pregnancy, first trimester 673.23  O83.212 Thromboembolism in pregnancy, second trimester 673.23  O83.213 Thromboembolism in pregnancy, third trimester 673.24  O83.23 Thromboembolism in puerperium  Adapted from: 1. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy P-M, Fine MJ. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041–1046.  2. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011;171:831–837.     
Code Sepsis I protocol Version 3.0 
 39 B.3 Deep vein thrombosis diagnosis codes1,2  ICD-9 ICD-10 Description (from ICD-10)  451.11  I80.10 Phlebitis/thrombophlebitis of unspecified femoral vein 451.11  I80.11  Phlebitis/thrombophlebitis of right femoral vein 451.11  I80.12  Phlebitis/thrombophlebitis of left femoral vein 451.11  I80.13  Phlebitis/thrombophlebitis of bilateral femoral vein 451.19  I80.201 Phlebitis/thrombophlebitis of unspecified deep vessels of right lower extremity 451.19  I80.202 Phlebitis/thrombophlebitis of unspecified deep vessels of left lower extremity 451.19  I80.203 Phlebitis/thrombophlebitis of unspecified deep vessels of bilateral lower extremity 451.19  I80.209 Phlebitis/thrombophlebitis of unspecified deep vessels of unspecified lower extremity 451.19  I80.221 Phlebitis/thrombophlebitis of right popliteal vein  451.19  I80.222 Phlebitis/thrombophlebitis of right popliteal vein 451.19  I80.223 Phlebitis/thrombophlebitis of bilateral popliteal vein 451.19  I80.229 Phlebitis/thrombophlebitis of unspecified popliteal vein 451.19  I80.231 Phlebitis/thrombophlebitis of right tibial vein  451.19  I80.232 Phlebitis/thrombophlebitis of right tibial vein 451.19  I80.233 Phlebitis/thrombophlebitis of bilateral tibial vein 451.19  I80.239 Phlebitis/thrombophlebitis of unspecified tibial vein 451.19  I80.291 Phlebitis/thrombophlebitis of other deep vessels of right lower extremity 451.19  I80.292 Phlebitis/thrombophlebitis of other deep vessels of left lower extremity 451.19  I80.293 Phlebitis/thrombophlebitis of other deep vessels of bilateral lower extremity 451.19  I80.299 Phlebitis/thrombophlebitis of other deep vessels of unspecified lower extremity 451.81  I80.211  Phlebitis/thrombophlebitis of right iliac vein 451.81   I80.212 Phlebitis/thrombophlebitis of left iliac vein 451.81   I80.213  Phlebitis/thrombophlebitis of bilateral iliac vein 453.81   I80.219  Phlebitis/thrombophlebitis of unspecified iliac vein 451.11  I80.10 Phlebitis/thrombophlebitis of unspecified femoral vein 451.11  I80.11  Phlebitis/thrombophlebitis of right femoral vein 451.11  I80.12  Phlebitis/thrombophlebitis of left femoral vein 451.11  I80.13  Phlebitis/thrombophlebitis of bilateral femoral vein 451.19  I80.201 Phlebitis/thrombophlebitis of unspecified deep vessels of right lower extremity 451.19  I80.202 Phlebitis/thrombophlebitis of unspecified deep vessels of left lower extremity 451.19  I80.203 Phlebitis/thrombophlebitis of unspecified deep vessels of bilateral lower extremity 451.19  I80.209 Phlebitis/thrombophlebitis of unspecified deep vessels of unspecified lower extremity 451.19  I80.221 Phlebitis/thrombophlebitis of right popliteal vein  451.19  I80.222 Phlebitis/thrombophlebitis of right popliteal vein 451.19  I80.223 Phlebitis/thrombophlebitis of bilateral popliteal vein 451.19  I80.229 Phlebitis/thrombophlebitis of unspecified popliteal vein 451.19  I80.231 Phlebitis/thrombophlebitis of right tibial vein  451.19  I80.232 Phlebitis/thrombophlebitis of right tibial vein 451.19  I80.233 Phlebitis/thrombophlebitis of bilateral tibial vein 451.19  I80.239 Phlebitis/thrombophlebitis of unspecified tibial vein 451.19  I80.291 Phlebitis/thrombophlebitis of other deep vessels of right lower extremity 451.19  I80.292 Phlebitis/thrombophlebitis of other deep vessels of left lower extremity 451.19  I80.293 Phlebitis/thrombophlebitis of other deep vessels of bilateral lower extremity 451.19  I80.299 Phlebitis/thrombophlebitis of other deep vessels of unspecified lower extremity 
Code Sepsis I protocol Version 3.0 
 40 ICD-9 ICD-10 Description (from ICD-10) — CONTINUED  451.81  I80.211  Phlebitis/thrombophlebitis of right iliac vein 451.81   I80.212 Phlebitis/thrombophlebitis of left iliac vein 451.81   I80.213  Phlebitis/thrombophlebitis of bilateral iliac vein 453.81   I80.219  Phlebitis/thrombophlebitis of unspecified iliac vein 451.83   Phlebitis/thrombophlebitis of deep vein of upper extremity 453.40  I82.401 Acute embolism/thrombosis of unspecified deep veins of right lower extremity 453.40  I82.402 Acute embolism/thrombosis of unspecified deep veins of left lower extremity 453.40  I82.403 Acute embolism/thrombosis of unspecified deep veins of bilateral lower extremity 453.40  I82.409 Acute embolism/thrombosis of unspecified deep veins of unspecified lower extremity 453.40  I82.491 Acute embolism/thrombosis of other deep veins of right lower extremity 453.40  I82.492 Acute embolism/thrombosis of other deep veins of left lower extremity 453.40  I82.493 Acute embolism/thrombosis of other deep veins of bilateral lower extremity 453.40  I82.499 Acute embolism/thrombosis of other deep veins of unspecified lower extremity 453.41  I82.411 Acute embolism/thrombosis of right femoral vein 453.41  I82.412 Acute embolism/thrombosis of left femoral vein 453.41  I82.413 Acute embolism/thrombosis of bilateral femoral vein 453.41  I82.419 Acute embolism/thrombosis of unspecified femoral vein 453.41  I82.421 Acute embolism/thrombosis of right iliac vein 453.41  I82.422 Acute embolism/thrombosis of left iliac vein 453.41  I82.423 Acute embolism/thrombosis of bilateral iliac vein 453.41  I82.429 Acute embolism/thrombosis of unspecified iliac vein 453.41  I82.4Y1 Acute embolism/thrombosis of unspecified veins of right proximal lower extremity 453.41  I82.4Y2 Acute embolism/thrombosis of unspecified veins of left proximal lower extremity 453.41  I82.4Y3 Acute embolism/thrombosis of unspecified veins of bilateral proximal lower extremity 453.41  I82.4Y9 Acute embolism/thrombosis of unspecified veins of unspecified prox lower extremity 453.42  I82.431 Acute embolism/thrombosis of right popliteal vein 453.42  I82.432 Acute embolism/thrombosis of left popliteal vein 453.42  I82.433 Acute embolism/thrombosis of bilateral popliteal vein 453.42  I82.439 Acute embolism/thrombosis of unspecified popliteal vein 453.42  I82.441 Acute embolism/thrombosis of right tibial vein 453.42  I82.442 Acute embolism/thrombosis of left tibial vein 453.42  I82.443 Acute embolism/thrombosis of bilateral tibial vein 453.42  I82.449 Acute embolism/thrombosis of unspecified tibial vein 453.42  I82.4Z1 Acute embolism/thrombosis of unspecified veins of right distal lower extremity 453.42  I82.4Z2 Acute embolism/thrombosis of unspecified veins of left distal lower extremity 453.42  I82.4Z3 Acute embolism/thrombosis of unspecified veins of bilateral distal lower extremity 453.42  I82.4Z9 Acute embolism/thrombosis of unspecified veins of unspecified distal lower extremity   I82.621 Acute embolism/thrombosis of deep veins of right upper extremity   I82.622 Acute embolism/thrombosis of deep veins of left upper extremity   I82.623 Acute embolism/thrombosis of deep veins of bilateral upper extremity   I82.629 Acute embolism/thrombosis of deep veins of unspecified upper extremity   
Code Sepsis I protocol Version 3.0 
 41  ICD-9 ICD-10 Description (from ICD-10) — CONTINUED  671.30  O22.30 Deep phlebothrombosis in pregnancy, unspecified trimester 671.31  O87.1 Deep phlebothrombosis in the peurperium 671.33  O22.31 Deep phlebothrombosis in pregnancy, first trimester 671.33  O22.32 Deep phlebothrombosis in pregnancy, second trimester 671.33  O22.33 Deep phlebothrombosis in pregnancy, third trimester  671.40  O87.1 Deep phlebothrombosis, postpartum, unspecified as to episode of care 671.42  O87.1 Deep phlebothrombosis, postpartum, delivered 671.44  O87.1 Deep phlebothrombosis, postpartum, postpartum condition   Adapted from: 1. White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Gammon H, Schmaltz S, Romano PS. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010;126:61–67.  2. Kniffin WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861–866.     
Code Sepsis I protocol Version 3.0 
 42 APPENDIX C — Diagnosis codes for adverse drug reaction  Adapted from:  Hohl CM, Karpov A, Reddekopp L, Doyle-Waters M, Stausberg J. ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc. 2014;21:547–57.   ICD-10-CM Anaphylaxis Description A0471  Enterocolitis due to Clostridium difficile, recurrent A0472  Enterocolitis due to Clostridium difficile, not specified as recurrent D590  Drug-induced autoimmune hemolytic anemia D592  Drug-induced nonautoimmune hemolytic anemia D7212  Drug rash with eosinophilia and systemic symptoms syndrome E064  Drug-induced thyroiditis E160  Drug-induced hypoglycemia without coma G210  Malignant neuroleptic syndrome G2402  Drug induced acute dystonia G2409  Other drug induced dystonia G251  Drug-induced tremor G4440  Drug-induced headache, not elsewhere classified, not intractable G4441  Drug-induced headache, not elsewhere classified, intractable G620  Drug-induced polyneuropathy G720  Drug-induced myopathy I427  Cardiomyopathy due to drug and external agent I952  Hypotension due to drugs J702  Acute drug-induced interstitial lung disorders J704  Drug-induced interstitial lung disorders, unspecified K710  Toxic liver disease with cholestasis K7110  Toxic liver disease with hepatic necrosis, without coma K7111  Toxic liver disease with hepatic necrosis, with coma K712  Toxic liver disease with acute hepatitis K716  Toxic liver disease with hepatitis, not elsewhere classified K719  Toxic liver disease, unspecified K8530  Drug induced acute pancreatitis without necrosis or infection K8531  Drug induced acute pancreatitis with uninfected necrosis K8532  Drug induced acute pancreatitis with infected necrosis L233  Allergic contact dermatitis due to drugs in contact with skin L244  Irritant contact dermatitis due to drugs in contact with skin L251  Unspecified contact dermatitis due to drugs in contact with skin L270  Generalized skin eruption due to drugs and medicaments taken internally L271  Localized skin eruption due to drugs and medicaments taken internally L278  Dermatitis due to other substances taken internally L279  Dermatitis due to unspecified substance taken internally L500  Allergic urticaria L509  Urticaria, unspecified L510  Nonbullous erythema multiforme L511  Stevens-Johnson syndrome L512  Toxic epidermal necrolysis [Lyell] 
Code Sepsis I protocol Version 3.0 
 43 ICD-10-CM Anaphylaxis Description L513  Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome L518  Other erythema multiforme L519  Erythema multiforme, unspecified L52  Erythema nodosum L530  Toxic erythema L531  Erythema annulare centrifugum N141  Nephropathy induced by other drugs, medicaments and biological substances N142  Nephropathy induced by unspecified drug, medicament or biological substance N144  Toxic nephropathy, not elsewhere classified R502  Drug induced fever T360X1A  Poisoning by penicillins, accidental (unintentional), initial encounter T360X1D  Poisoning by penicillins, accidental (unintentional), subsequent encounter T360X1S  Poisoning by penicillins, accidental (unintentional), sequela T360X4A  Poisoning by penicillins, undetermined, initial encounter T360X4D  Poisoning by penicillins, undetermined, subsequent encounter T360X4S  Poisoning by penicillins, undetermined, sequela T360X5A  Adverse effect of penicillins, initial encounter T360X5D  Adverse effect of penicillins, subsequent encounter T360X5S  Adverse effect of penicillins, sequela T360X6A  Underdosing of penicillins, initial encounter T360X6D  Underdosing of penicillins, subsequent encounter T360X6S  Underdosing of penicillins, sequela T361X1A  Poisoning by cephalosporins and other beta-lactam antibiotics, accidental (unintentional), initial encounter T361X1D  Poisoning by cephalosporins and other beta-lactam antibiotics, accidental (unintentional), subsequent encounter T361X1S  Poisoning by cephalosporins and other beta-lactam antibiotics, accidental (unintentional), sequela T361X4A  Poisoning by cephalosporins and other beta-lactam antibiotics, undetermined, initial encounter T361X4D  Poisoning by cephalosporins and other beta-lactam antibiotics, undetermined, subsequent encounter T361X4S  Poisoning by cephalosporins and other beta-lactam antibiotics, undetermined, sequela T361X5A  Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter T361X5D  Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter T361X5S  Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela T361X6A  Underdosing of cephalosporins and other beta-lactam antibiotics, initial encounter T361X6D  Underdosing of cephalosporins and other beta-lactam antibiotics, subsequent encounter T361X6S  Underdosing of cephalosporins and other beta-lactam antibiotics, sequela 
Code Sepsis I protocol Version 3.0 
 44 ICD-10-CM Anaphylaxis Description T362X1A  Poisoning by chloramphenicol group, accidental (unintentional), initial encounter T362X1D  Poisoning by chloramphenicol group, accidental (unintentional), subsequent encounter T362X1S  Poisoning by chloramphenicol group, accidental (unintentional), sequela T362X4A  Poisoning by chloramphenicol group, undetermined, initial encounter T362X4D  Poisoning by chloramphenicol group, undetermined, subsequent encounter T362X4S  Poisoning by chloramphenicol group, undetermined, sequela T362X5A  Adverse effect of chloramphenicol group, initial encounter T362X5D  Adverse effect of chloramphenicol group, subsequent encounter T362X5S  Adverse effect of chloramphenicol group, sequela T362X6A  Underdosing of chloramphenicol group, initial encounter T362X6D  Underdosing of chloramphenicol group, subsequent encounter T362X6S  Underdosing of chloramphenicol group, sequela T363X1A  Poisoning by macrolides, accidental (unintentional), initial encounter T363X1D  Poisoning by macrolides, accidental (unintentional), subsequent encounter T363X1S  Poisoning by macrolides, accidental (unintentional), sequela T363X4A  Poisoning by macrolides, undetermined, initial encounter T363X4D  Poisoning by macrolides, undetermined, subsequent encounter T363X4S  Poisoning by macrolides, undetermined, sequela T363X5A  Adverse effect of macrolides, initial encounter T363X5D  Adverse effect of macrolides, subsequent encounter T363X5S  Adverse effect of macrolides, sequela T363X6A  Underdosing of macrolides, initial encounter T363X6D  Underdosing of macrolides, subsequent encounter T363X6S  Underdosing of macrolides, sequela T364X1A  Poisoning by tetracyclines, accidental (unintentional), initial encounter T364X1D  Poisoning by tetracyclines, accidental (unintentional), subsequent encounter T364X1S  Poisoning by tetracyclines, accidental (unintentional), sequela T364X4A  Poisoning by tetracyclines, undetermined, initial encounter T364X4D  Poisoning by tetracyclines, undetermined, subsequent encounter T364X4S  Poisoning by tetracyclines, undetermined, sequela T364X5A  Adverse effect of tetracyclines, initial encounter T364X5D  Adverse effect of tetracyclines, subsequent encounter T364X5S  Adverse effect of tetracyclines, sequela T364X6A  Underdosing of tetracyclines, initial encounter T364X6D  Underdosing of tetracyclines, subsequent encounter T364X6S  Underdosing of tetracyclines, sequela T365X1A  Poisoning by aminoglycosides, accidental (unintentional), initial encounter T365X1D  Poisoning by aminoglycosides, accidental (unintentional), subsequent encounter T365X1S  Poisoning by aminoglycosides, accidental (unintentional), sequela T365X4A  Poisoning by aminoglycosides, undetermined, initial encounter 
Code Sepsis I protocol Version 3.0 
 45 ICD-10-CM Anaphylaxis Description T365X4D  Poisoning by aminoglycosides, undetermined, subsequent encounter T365X4S  Poisoning by aminoglycosides, undetermined, sequela T365X5A  Adverse effect of aminoglycosides, initial encounter T365X5D  Adverse effect of aminoglycosides, subsequent encounter T365X5S  Adverse effect of aminoglycosides, sequela T365X6A  Underdosing of aminoglycosides, initial encounter T365X6D  Underdosing of aminoglycosides, subsequent encounter T365X6S  Underdosing of aminoglycosides, sequela T366X1A  Poisoning by rifampicins, accidental (unintentional), initial encounter T366X1D  Poisoning by rifampicins, accidental (unintentional), subsequent encounter T366X1S  Poisoning by rifampicins, accidental (unintentional), sequela T366X4A  Poisoning by rifampicins, undetermined, initial encounter T366X4D  Poisoning by rifampicins, undetermined, subsequent encounter T366X4S  Poisoning by rifampicins, undetermined, sequela T366X5A  Adverse effect of rifampicins, initial encounter T366X5D  Adverse effect of rifampicins, subsequent encounter T366X5S  Adverse effect of rifampicins, sequela T366X6A  Underdosing of rifampicins, initial encounter T366X6D  Underdosing of rifampicins, subsequent encounter T366X6S  Underdosing of rifampicins, sequela T367X1A  Poisoning by antifungal antibiotics, systemically used, accidental (unintentional), initial encounter T367X1D  Poisoning by antifungal antibiotics, systemically used, accidental (unintentional), subsequent encounter T367X1S  Poisoning by antifungal antibiotics, systemically used, accidental (unintentional), sequela T367X4A  Poisoning by antifungal antibiotics, systemically used, undetermined, initial encounter T367X4D  Poisoning by antifungal antibiotics, systemically used, undetermined, subsequent encounter T367X4S  Poisoning by antifungal antibiotics, systemically used, undetermined, sequela T367X5A  Adverse effect of antifungal antibiotics, systemically used, initial encounter T367X5D  Adverse effect of antifungal antibiotics, systemically used, subsequent encounter T367X5S  Adverse effect of antifungal antibiotics, systemically used, sequela T367X6A  Underdosing of antifungal antibiotics, systemically used, initial encounter T367X6D  Underdosing of antifungal antibiotics, systemically used, subsequent encounter T367X6S  Underdosing of antifungal antibiotics, systemically used, sequela T368X1A  Poisoning by other systemic antibiotics, accidental (unintentional), initial encounter T368X1D  Poisoning by other systemic antibiotics, accidental (unintentional), subsequent encounter T368X1S  Poisoning by other systemic antibiotics, accidental (unintentional), 
Code Sepsis I protocol Version 3.0 
 46 ICD-10-CM Anaphylaxis Description sequela T368X4A  Poisoning by other systemic antibiotics, undetermined, initial encounter T368X4D  Poisoning by other systemic antibiotics, undetermined, subsequent encounter T368X4S  Poisoning by other systemic antibiotics, undetermined, sequela T368X5A  Adverse effect of other systemic antibiotics, initial encounter T368X5D  Adverse effect of other systemic antibiotics, subsequent encounter T368X5S  Adverse effect of other systemic antibiotics, sequela T368X6A  Underdosing of other systemic antibiotics, initial encounter T368X6D  Underdosing of other systemic antibiotics, subsequent encounter T368X6S  Underdosing of other systemic antibiotics, sequela T3691XA  Poisoning by unspecified systemic antibiotic, accidental (unintentional), initial encounter T3691XD  Poisoning by unspecified systemic antibiotic, accidental (unintentional), subsequent encounter T3691XS  Poisoning by unspecified systemic antibiotic, accidental (unintentional), sequela T3694XA  Poisoning by unspecified systemic antibiotic, undetermined, initial encounter T3694XD  Poisoning by unspecified systemic antibiotic, undetermined, subsequent encounter T3694XS  Poisoning by unspecified systemic antibiotic, undetermined, sequela T3695XA  Adverse effect of unspecified systemic antibiotic, initial encounter T3695XD  Adverse effect of unspecified systemic antibiotic, subsequent encounter T3695XS  Adverse effect of unspecified systemic antibiotic, sequela T3696XA  Underdosing of unspecified systemic antibiotic, initial encounter T3696XD  Underdosing of unspecified systemic antibiotic, subsequent encounter T3696XS  Underdosing of unspecified systemic antibiotic, sequela T370X1A  Poisoning by sulfonamides, accidental (unintentional), initial encounter T370X1D  Poisoning by sulfonamides, accidental (unintentional), subsequent encounter T370X1S  Poisoning by sulfonamides, accidental (unintentional), sequela T370X4A  Poisoning by sulfonamides, undetermined, initial encounter T370X4D  Poisoning by sulfonamides, undetermined, subsequent encounter T370X4S  Poisoning by sulfonamides, undetermined, sequela T370X5A  Adverse effect of sulfonamides, initial encounter T370X5D  Adverse effect of sulfonamides, subsequent encounter T370X5S  Adverse effect of sulfonamides, sequela T370X6A  Underdosing of sulfonamides, initial encounter T370X6D  Underdosing of sulfonamides, subsequent encounter T370X6S  Underdosing of sulfonamides, sequela T371X1A  Poisoning by antimycobacterial drugs, accidental (unintentional), initial encounter T371X1D  Poisoning by antimycobacterial drugs, accidental (unintentional), subsequent encounter T371X1S  Poisoning by antimycobacterial drugs, accidental (unintentional), sequela T371X4A  Poisoning by antimycobacterial drugs, undetermined, initial encounter 
Code Sepsis I protocol Version 3.0 
 47 ICD-10-CM Anaphylaxis Description T371X4D  Poisoning by antimycobacterial drugs, undetermined, subsequent encounter T371X4S  Poisoning by antimycobacterial drugs, undetermined, sequela T371X5A  Adverse effect of antimycobacterial drugs, initial encounter T371X5D  Adverse effect of antimycobacterial drugs, subsequent encounter T371X5S  Adverse effect of antimycobacterial drugs, sequela T371X6A  Underdosing of antimycobacterial drugs, initial encounter T371X6D  Underdosing of antimycobacterial drugs, subsequent encounter T371X6S  Underdosing of antimycobacterial drugs, sequela T372X1A  Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional), initial encounter T372X1D  Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional), subsequent encounter T372X1S  Poisoning by antimalarials and drugs acting on other blood protozoa, accidental (unintentional), sequela T372X4A  Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined, initial encounter T372X4D  Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined, subsequent encounter T372X4S  Poisoning by antimalarials and drugs acting on other blood protozoa, undetermined, sequela T372X5A  Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter T372X5D  Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter T372X5S  Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela T372X6A  Underdosing of antimalarials and drugs acting on other blood protozoa, initial encounter T372X6D  Underdosing of antimalarials and drugs acting on other blood protozoa, subsequent encounter T372X6S  Underdosing of antimalarials and drugs acting on other blood protozoa, sequela T373X1A  Poisoning by other antiprotozoal drugs, accidental (unintentional), initial encounter T373X1D  Poisoning by other antiprotozoal drugs, accidental (unintentional), subsequent encounter T373X1S  Poisoning by other antiprotozoal drugs, accidental (unintentional), sequela T373X4A  Poisoning by other antiprotozoal drugs, undetermined, initial encounter T373X4D  Poisoning by other antiprotozoal drugs, undetermined, subsequent encounter T373X4S  Poisoning by other antiprotozoal drugs, undetermined, sequela T373X5A  Adverse effect of other antiprotozoal drugs, initial encounter T373X5D  Adverse effect of other antiprotozoal drugs, subsequent encounter T373X5S  Adverse effect of other antiprotozoal drugs, sequela T373X6A  Underdosing of other antiprotozoal drugs, initial encounter 
Code Sepsis I protocol Version 3.0 
 48 ICD-10-CM Anaphylaxis Description T373X6D  Underdosing of other antiprotozoal drugs, subsequent encounter T373X6S  Underdosing of other antiprotozoal drugs, sequela T374X1A  Poisoning by anthelminthics, accidental (unintentional), initial encounter T374X1D  Poisoning by anthelminthics, accidental (unintentional), subsequent encounter T374X1S  Poisoning by anthelminthics, accidental (unintentional), sequela T374X4A  Poisoning by anthelminthics, undetermined, initial encounter T374X4D  Poisoning by anthelminthics, undetermined, subsequent encounter T374X4S  Poisoning by anthelminthics, undetermined, sequela T374X5A  Adverse effect of anthelminthics, initial encounter T374X5D  Adverse effect of anthelminthics, subsequent encounter T374X5S  Adverse effect of anthelminthics, sequela T374X6A  Underdosing of anthelminthics, initial encounter T374X6D  Underdosing of anthelminthics, subsequent encounter T374X6S  Underdosing of anthelminthics, sequela T375X1A  Poisoning by antiviral drugs, accidental (unintentional), initial encounter T375X1D  Poisoning by antiviral drugs, accidental (unintentional), subsequent encounter T375X1S  Poisoning by antiviral drugs, accidental (unintentional), sequela T375X4A  Poisoning by antiviral drugs, undetermined, initial encounter T375X4D  Poisoning by antiviral drugs, undetermined, subsequent encounter T375X4S  Poisoning by antiviral drugs, undetermined, sequela T375X5A  Adverse effect of antiviral drugs, initial encounter T375X5D  Adverse effect of antiviral drugs, subsequent encounter T375X5S  Adverse effect of antiviral drugs, sequela T375X6A  Underdosing of antiviral drugs, initial encounter T375X6D  Underdosing of antiviral drugs, subsequent encounter T375X6S  Underdosing of antiviral drugs, sequela T378X1A  Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), initial encounter T378X1D  Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), subsequent encounter T378X1S  Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), sequela T378X4A  Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, initial encounter T378X4D  Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, subsequent encounter T378X4S  Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, sequela T378X5A  Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter T378X5D  Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter T378X5S  Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela T378X6A  Underdosing of other specified systemic anti-infectives and antiparasitics, 
Code Sepsis I protocol Version 3.0 
 49 ICD-10-CM Anaphylaxis Description initial encounter T378X6D  Underdosing of other specified systemic anti-infectives and antiparasitics, subsequent encounter T378X6S  Underdosing of other specified systemic anti-infectives and antiparasitics, sequela T3791XA  Poisoning by unspecified systemic anti-infective and antiparasitics, accidental (unintentional), initial encounter T3791XD  Poisoning by unspecified systemic anti-infective and antiparasitics, accidental (unintentional), subsequent encounter T3791XS  Poisoning by unspecified systemic anti-infective and antiparasitics, accidental (unintentional), sequela T3794XA  Poisoning by unspecified systemic anti-infective and antiparasitics, undetermined, initial encounter T3794XD  Poisoning by unspecified systemic anti-infective and antiparasitics, undetermined, subsequent encounter T3794XS  Poisoning by unspecified systemic anti-infective and antiparasitics, undetermined, sequela T3795XA  Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter T3795XD  Adverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter T3795XS  Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela T3796XA  Underdosing of unspecified systemic anti-infectives and antiparasitics, initial encounter T3796XD  Underdosing of unspecified systemic anti-infectives and antiparasitics, subsequent encounter T3796XS  Underdosing of unspecified systemic anti-infectives and antiparasitics, sequela T431X5A  Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter T431X5D  Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter T431X5S  Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela T43215A  Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter T43215D  Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter T43215S  Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela T43225A  Adverse effect of selective serotonin reuptake inhibitors, initial encounter T43225D  Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter T43225S  Adverse effect of selective serotonin reuptake inhibitors, sequela T50901A  Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional), initial encounter T50901D  Poisoning by unspecified drugs, medicaments and biological substances, 
Code Sepsis I protocol Version 3.0 
 50 ICD-10-CM Anaphylaxis Description accidental (unintentional), subsequent encounter T50901S  Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional), sequela T50904A  Poisoning by unspecified drugs, medicaments and biological substances, undetermined, initial encounter T50904D  Poisoning by unspecified drugs, medicaments and biological substances, undetermined, subsequent encounter T50904S  Poisoning by unspecified drugs, medicaments and biological substances, undetermined, sequela T50905A  Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter T50905D  Adverse effect of unspecified drugs, medicaments and biological substances, subsequent encounter T50905S  Adverse effect of unspecified drugs, medicaments and biological substances, sequela T50906A  Underdosing of unspecified drugs, medicaments and biological substances, initial encounter T50906D  Underdosing of unspecified drugs, medicaments and biological substances, subsequent encounter T50906S  Underdosing of unspecified drugs, medicaments and biological substances, sequela T50991A  Poisoning by other drugs, medicaments and biological substances, accidental (unintentional), initial encounter T50991D  Poisoning by other drugs, medicaments and biological substances, accidental (unintentional), subsequent encounter T50991S  Poisoning by other drugs, medicaments and biological substances, accidental (unintentional), sequela T50994A  Poisoning by other drugs, medicaments and biological substances, undetermined, initial encounter T50994D  Poisoning by other drugs, medicaments and biological substances, undetermined, subsequent encounter T50994S  Poisoning by other drugs, medicaments and biological substances, undetermined, sequela T50995A  Adverse effect of other drugs, medicaments and biological substances, initial encounter T50995D  Adverse effect of other drugs, medicaments and biological substances, subsequent encounter T50995S  Adverse effect of other drugs, medicaments and biological substances, sequela T50996A  Underdosing of other drugs, medicaments and biological substances, initial encounter T50996D  Underdosing of other drugs, medicaments and biological substances, subsequent encounter T50996S  Underdosing of other drugs, medicaments and biological substances, sequela T782XXA X Anaphylactic shock, unspecified, initial encounter T782XXD X Anaphylactic shock, unspecified, subsequent encounter 
Code Sepsis I protocol Version 3.0 
 51 ICD-10-CM Anaphylaxis Description T782XXS X Anaphylactic shock, unspecified, sequela T783XXA X Angioneurotic edema, initial encounter T783XXD X Angioneurotic edema, subsequent encounter T783XXS X Angioneurotic edema, sequela T7840XA  Allergy, unspecified, initial encounter T7840XD  Allergy, unspecified, subsequent encounter T7840XS  Allergy, unspecified, sequela T7841XA  Arthus phenomenon, initial encounter T7841XD  Arthus phenomenon, subsequent encounter T7841XS  Arthus phenomenon, sequela T7849XA  Other allergy, initial encounter T7849XD  Other allergy, subsequent encounter T7849XS  Other allergy, sequela T788XXA  Other adverse effects, not elsewhere classified, initial encounter T788XXD  Other adverse effects, not elsewhere classified, subsequent encounter T788XXS  Other adverse effects, not elsewhere classified, sequela T8051XA X Anaphylactic reaction due to administration of blood and blood products, initial encounter T8051XD X Anaphylactic reaction due to administration of blood and blood products, subsequent encounter T8051XS X Anaphylactic reaction due to administration of blood and blood products, sequela T8052XA X Anaphylactic reaction due to vaccination, initial encounter T8052XD X Anaphylactic reaction due to vaccination, subsequent encounter T8052XS X Anaphylactic reaction due to vaccination, sequela T8059XA X Anaphylactic reaction due to other serum, initial encounter T8059XD X Anaphylactic reaction due to other serum, subsequent encounter T8059XS X Anaphylactic reaction due to other serum, sequela T8089XA  Other complications following infusion, transfusion and therapeutic injection, initial encounter T8089XD  Other complications following infusion, transfusion and therapeutic injection, subsequent encounter T8089XS  Other complications following infusion, transfusion and therapeutic injection, sequela T8090XA  Unspecified complication following infusion and therapeutic injection, initial encounter T8090XD  Unspecified complication following infusion and therapeutic injection, subsequent encounter T8090XS  Unspecified complication following infusion and therapeutic injection, sequela T886XXA X Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter T886XXD X Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounter T886XXS X Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela 
Code Sepsis I protocol Version 3.0 
 52 ICD-10-CM Anaphylaxis Description T887XXA  Unspecified adverse effect of drug or medicament, initial encounter T888XXA  Other specified complications of surgical and medical care, not elsewhere classified, initial encounter T889XXA  Complication of surgical and medical care, unspecified, initial encounter Y631  Incorrect dilution of fluid used during infusion Y638  Failure in dosage during other surgical and medical care Y639  Failure in dosage during unspecified surgical and medical care Y640  Contaminated medical or biological substance, transfused or infused Y641  Contaminated medical or biological substance, injected or used for immunization Y651  Wrong fluid used in infusion Y66  Nonadministration of surgical and medical care Y69  Unspecified misadventure during surgical and medical care  